

Weekly

January 5, 2007 / Vol. 55 / Nos. 51 & 52

National Birth Defects Prevention Month and National Folic Acid Awareness Week

January is National Birth Defects Prevention Month, and January 8–14 is National Folic Acid Awareness Week. Birth defects affect approximately one in 33 newborns in the United States. The cost of lifetime care for infants born in a single year with one or more of 17 severe birth defects has been estimated at \$6 billion (1).

CDC has issued recommendations for all women and men of childbearing age to improve their health throughout their lifespans, especially if they are planning to have children (2). Health-care professionals should encourage men and women to adopt healthy behaviors, such as having regular medical check-ups, planning their pregnancy with their partner, and avoiding alcohol, tobacco, and illicit drugs.

For women, taking the B vitamin folic acid before and during early pregnancy can prevent serious birth defects of the spine and brain; however, folic acid use has not changed substantially (*3*). Information about CDC's birth defect–prevention activities is available at http://www.cdc. gov/ncbddd, and information about National Birth Defects Prevention Month is available at http://www. nbdpn.org/current/resources/bdpm2007.html.


References

- 1. CDC. Economic costs of birth defects and cerebral palsy—United States, 1992. MMWR 1995;44:694–9.
- 2. CDC. Recommendations to improve preconception health and health care—United States. A report of the CDC/ATSDR Preconception Care Work Group and the Select Panel on Preconception Care. MMWR 2006;55(No. RR-6).
- 3. CDC. Use of dietary supplements containing folic acid among women of childbearing age—United States, 2005. MMWR 2005; 54:955–8.

Folate Status in Women of Childbearing Age, by Race/Ethnicity — United States, 1999–2000, 2001–2002, and 2003–2004

Fortification of enriched cereal-grain products with folic acid to help prevent pregnancies affected by a neural tube defect (NTD) (e.g., spina bifida or anencephaly) became mandatory in the United States in January 1998. Data from the 1999– 2000 National Health and Nutrition Examination Survey (NHANES) indicated that median serum folate* concentrations in nonpregnant women of childbearing age had increased substantially, compared with concentrations during a period (1988–1994) before fortification was mandated (*1*). This report uses NHANES data to update those findings and assess trends in serum folate and red blood cell (RBC) folate levels[†] by race/ethnicity from the 1999–2000 survey through

^{*} Folate is the form of the B vitamin that occurs naturally in foods. Folic acid is the synthetic form of folate used in vitamin supplements and to fortify foods. [†] The two measurements conventionally used to assess the amount of folate in the body. Serum folate fluctuates with daily intake; RBC folate integrates folate intake over a period of several months.



DEPARTMENT OF HEALTH AND HUMAN SERVICES CENTERS FOR DISEASE CONTROL AND PREVENTION

The *MMWR* series of publications is published by the Coordinating Center for Health Information and Service, Centers for Disease Control and Prevention (CDC), U.S. Department of Health and Human Services, Atlanta, GA 30333.

Suggested Citation: Centers for Disease Control and Prevention. [Article title]. MMWR 2006;55:[inclusive page numbers].

Centers for Disease Control and Prevention

Julie L. Gerberding, MD, MPH *Director* Tanja Popovic, MD, PhD (*Acting*) *Chief Science Officer*

James W. Stephens, PhD (*Acting*) *Associate Director for Science* Steven L. Solomon, MD

Director, Coordinating Center for Health Information and Service Jay M. Bernhardt, PhD, MPH Director, National Center for Health Marketing Judith R. Aguilar

(Acting) Director, Division of Health Information Dissemination (Proposed)

Editorial and Production Staff

John S. Moran, MD, MPH (*Acting*) *Editor*, MMWR *Series* Suzanne M. Hewitt, MPA

Managing Editor, MMWR Series Douglas W. Weatherwax (Acting) Lead Technical Writer-Editor

> Catherine H. Bricker, MS Jude C. Rutledge Writers-Editors

Beverly J. Holland Lead Visual Information Specialist Lynda G. Cupell Malbea A. LaPete

Visual Information Specialists Quang M. Doan, MBA Erica R. Shaver

Information Technology Specialists

Editorial Board

William L. Roper, MD, MPH, Chapel Hill, NC, Chairman Virginia A. Caine, MD, Indianapolis, IN David W. Fleming, MD, Seattle, WA William E. Halperin, MD, DrPH, MPH, Newark, NJ Margaret A. Hamburg, MD, Washington, DC King K. Holmes, MD, PhD, Seattle, WA Deborah Holtzman, PhD, Atlanta, GA John K. Iglehart, Bethesda, MD Dennis G. Maki, MD, Madison, WI Sue Mallonee, MPH, Oklahoma City, OK Stanley A. Plotkin, MD, Doylestown, PA Patricia Quinlisk, MD, MPH, Des Moines, IA Patrick L. Remington, MD, MPH, Madison, WI Barbara K. Rimer, DrPH, Chapel Hill, NC John V. Rullan, MD, MPH, San Juan, PR Anne Schuchat, MD, Atlanta, GA Dixie E. Snider, MD, MPH, Atlanta, GA John W. Ward, MD, Atlanta, GA

the 2003–2004 survey. The results of these comparisons indicated that median serum folate concentrations among nonpregnant women of childbearing age decreased 16% from 1999–2000 through 2003–2004, and RBC folate concentrations decreased 8%. All women of childbearing age who are capable of becoming pregnant should consume 400 μ g of folic acid daily to reduce the occurrence of NTD-affected pregnancies (2).

In 1992, the Public Health Service recommended that all women of childbearing age who are capable of becoming pregnant consume 400 μ g of folic acid daily to reduce the number of cases of NTDs (2). In 1996, a final rule published by the Food and Drug Administration (FDA) required the addition of folic acid to a range of enriched cereal-grain products (e.g., bread, rolls, macaroni products, rice, corn meal, corn grits, and farina); the manufacturers' full-compliance date was January 1998 (3). In addition to improved dietary habits and folic acid fortification, the Public Health Service also recommended the use of dietary supplements containing folic acid (2); however, survey data have not indicated a substantial change in supplement use since the fortification mandate (4).

NHANES 1999-2000, 2001-2002, and 2003-2004 are annual surveys of persons of all ages selected through a stratified, multistage probability sampling of the civilian, noninstitutionalized U.S. population. A household interview and physical examination are conducted for each survey participant; blood samples are collected by venipuncture during the physical examination. For all study years, serum folate and RBC folate concentrations were measured by CDC (1). Long-term quality-control data for these assays indicated no analytic drift; external proficiency testing challenges also indicated stable performance. Serum folate and RBC folate concentrations for nonpregnant women aged 15-44 years were distributed by percentile, and medians were calculated. Because no satisfactory nonparametric approach exists for statistical analysis of survey data that compares medians, geometric mean serum folate and RBC folate concentrations were calculated; trends in geometric means from 1999-2000 through 2003–2004 were evaluated using a t test calculated from a linear regression model. The values derived for the medians and geometric means were consistent.

During 2001–2002 and 2003–2004, median (50th percentile) serum folate concentrations among women aged 15–44 years were 11.4 ng/mL and 10.6 ng/mL, respectively. Thus, a statistically significant 16% decline was observed from 1999– 2000 (12.6 ng/mL) through 2003–2004 based on comparison of geometric means (p<0.001) (Table 1). Similarly, RBC folate concentrations decreased 8%, from 255 ng/mL during 1999–2000 to 235 ng/mL during 2003–2004 (p=0.028).

	No. in		10th	2	25th	:	50th		75th		90th
Concentration/Period	sample	ng/mL	(95% CI*)	ng/mL	(95% CI)	ng/mL	(95% CI)	ng/mL	(95% CI)	ng/mL	. (95% CI)
Serum folate											
1999–2000	1,386	6.3	(5.9–6.7)	8.9	(8.3–9.5)	12.6	(11.7–13.5)	17.3	(16.1–18.7)	24.7	(21.4-27.8)
2001–2002	1,555	6.4	(5.9–6.9)	8.5	(8.1–9.1)	11.4	(11.1–12.0)	15.2	(14.9–15.9)	19.7	(19.2–20.8)
2003–2004	1,373	6.0	(5.6-6.5)	7.8	(7.5-8.1)	10.6	(10.2–11.2)	14.1	(13.5–14.8)	18.5	(17.5-20.3)
Red blood cell folate											
1999–2000	1,392	164	(151–173)	200	(190–210)	255	(240–270)	329	(305–353)	409	(371–437)
2001–2002	1,568	163	(155–172)	208	(197–217)	260	(250-272)	318	(309-331)	395	(384-412)
2003–2004	1,385	155	(150–161)	188	(184–196)	235	(226–246)	298	(284–315)	367	(349–398)

TABLE 1. Serum folate and red blood cell folate concentrations among nonpregnant women aged 15–44 years, by percentile — National Health and Nutrition Examination Survey, United States, 1999–2000, 2001–2002, and 2003–2004

* Confidence interval.

When analyzed by race/ethnicity, median serum folate concentrations declined significantly from 1999–2000 through 2003–2004 among all three populations considered (non-Hispanic whites [p=0.008], non-Hispanic blacks [p=0.023], and Mexican Americans [p<0.001]). The largest decrease (16%) was noted among non-Hispanic whites (Table 2). However, the median serum folate concentration was lowest among non-Hispanic blacks during all three survey periods.

Although non-Hispanic white and Mexican-American women exceeded the 2010 national health objective (objective 16-16b) for median RBC folate concentration (220 ng/mL) during all three survey periods, non-Hispanic black women had not met this objective. Trend differences from 1999–2000 through 2003–2004 in RBC folate concentrations were not statistically significant among each of the three racial/ethnic populations (non-Hispanic whites [p=0.106], non-Hispanic blacks [p=0.076], and Mexican Americans [p=0.064]).

Reported by: *SL Boulet, DrPH, Q Yang, PhD, C Mai, MPH, J Mulinare, MD, National Center on Birth Defects and Developmental Disabilities; CM Pfeiffer, PhD, National Center on Environmental Health, CDC.*

Editorial Note: Previous data for all (pregnant and nonpregnant) women aged 15–44 years indicated that median serum folate levels increased from 4.8 ng/mL during 1988–1994 (NHANES III) to 13.0 ng/mL during NHANES 1999–2000;

similar increases were noted in RBC folate concentrations (1). However, the findings in this report suggest that folate concentrations among nonpregnant U.S. women of childbearing age declined from 1999-2000 through 2003-2004. These findings extend results from a recent study using NHANES data that observed a decrease in the mean serum folate concentration among women of all ages from 1999-2000 to 2001-2002 (5). Another recent study reported decreases in the prevalence of spina bifida and an encephaly among infants born to non-Hispanic white and Hispanic women when comparing data from 1995-1996 and 1997-1998 with data from 1998–2002 (the most recent available); these data suggest an association between NTD decreases and folic acid fortification (6). During 1995-2002, no significant change in the prevalence of NTDs was observed among infants born to non-Hispanic black women (6).

Changes in laboratory techniques or sampling biases between survey periods are unlikely to account for the declines in folate levels described in this report. More likely explanations include 1) changes over time in the proportion of women taking supplements containing folic acid, 2) decreased consumption of foods rich in natural folates or foods fortified with folic acid (i.e., enriched cereal-grain products), 3) variations in the amounts of folic acid added to enriched grain products since fortification was mandated, and 4)

TABLE 2. Median serum folate and red blood cell folate concentrations among nonpregnant women aged 15–44 years, by race/ ethnicity — National Health and Nutrition Examination Survey, United States, 1999–2000, 2001–2002, and 2003–2004

	Whi	te, non-Hi	spanic	Bla	ick, non-H	lispanic	Me	exican An	nerican
Concentration/Period	No. in sample	ng/mL	(95% CI*)	No. in sample	ng/mL	(95% CI)	No. in sample	ng/mL	(95% CI)
Serum folate									
1999–2000	426	13.4	(12.4–15.0)	329	10.0	(9.2–11.1)	501	11.1	(10.8–11.9)
2001–2002	607	12.1	(11.4–13.1)	378	9.5	(9.0-10.4)	452	10.6	(10.1 - 11.3)
2003–2004	561	11.3	(10.6–12.0)	391	8.5	(7.7–9.2)	332	10.0	(8.7–10.8)
Red blood cell folate									
1999–2000	427	273	(248–298)	332	207	(193–226)	503	241	(237–246)
2001–2002	612	275	(266–283)	382	199	(194–208)	453	245	(227–260)
2003–2004	566	247	(234–261)	397	196	(188–207)	333	235	(222–252)

* Confidence interval.

increases in risk factors associated with lower folate concentrations such as obesity. However, evidence to support these explanations is mixed. With the exception of an increase in 2004, no substantial change was observed during 1995–2005 in the proportion of women of childbearing age who reported using a dietary supplement containing folic acid (4). Slight and conflicting changes in U.S. food consumption patterns have been noted; these include lower fruit and vegetable intake during 1999-2000 than during 1994-1996 but increased consumption of whole grains since 1970 (7). In a 2005 survey, approximately 26% of women aged 18-45 years reported dieting during the preceding 6 months, and approximately 27% of dieters reported following low-carbohydrate diets; such diets might result in reductions in the amounts of fortified foods consumed (4). Another analysis also suggests that the mean folate content of certain enriched breads might have been reduced during 2000-2003; other enriched cerealgrain products were not tested in this analysis (8). Finally, the prevalence of obesity among women aged 17-49 years increased from 21.8% during 1988-1994 to 32.3% during 1999–2000 (*9*).

Disparities in serum folate and RBC folate concentrations among racial/ethnic groups have been reported previously (1,5); these might be attributable to differences in awareness of folic acid and use of dietary supplements containing folic acid (4). In this report, non-Hispanic white women, a population with historically higher levels of folate intake, had the largest decreases in both median serum folate and median RBC folate and accounted for most of the decreases in the overall study population. Although non-Hispanic whites and Mexican Americans have met the *Healthy People 2010* objective for median RBC folate concentration since 1999–2000, if folate intake continues to decrease overall, median concentrations might decrease to <220 ng/mL.

The findings in this report are subject to at least one limitation. No data from the National Birth Defects Prevention Network (NBDPN)[§] were available regarding the prevalence of NTDs during 2003–2004. This prevents comparison of NTD trends for 1999–2004 with trends in serum folate and RBC folate levels in women of childbearing age during the same period. Consequently, evaluating the effect of recent declines in folate levels on NTD prevalence will require additional data. In 1993, FDA's Folic Acid Subcommittee recommended a fortification strategy that would enable 90% of women of childbearing age to receive at least 400 μ g of folic acid per day from all sources (10). However, fortification alone, at the levels used, was not expected to provide 400 μ g of folic acid daily. To reduce the number of cases of NTDs, U.S. women of childbearing age who are capable of becoming pregnant should consume at least 400 μ g of folic acid daily through dietary supplements and fortified foods, in addition to a diet containing folate-rich foods. Continued monitoring of serum folate and RBC folate concentrations in U.S. women of childbearing age can help public health agencies modify existing policies and programs or implement new ones aimed at reducing the number of cases of NTDs.

Acknowledgments

The findings in this report are based, in part, on contributions by RS Kirby, PhD, Univ of Alabama at Birmingham, Alabama. JS Collins, PhD, Greenwood Genetic Center, Greenwood, South Carolina. JM Robbins, PhD, Univ of Arkansas for Medical Sciences, Little Rock, Arkansas. R Meyer, PhD, North Carolina State Center for Health Statistics, Raleigh, North Carolina. MA Canfield, PhD, Texas Dept of State Health Svcs. TJ Flood, MD, Arizona Dept of Health Svcs.

References

- 1. CDC. Folate status in women of childbearing age, by race/ethnicity— United States, 1999–2000. MMWR 2002;51:808–10.
- CDC. Recommendations for the use of folic acid to reduce the number of cases of spina bifida and other neural tube defects. MMWR 1992;41(No. RR-14).
- 3. Food and Drug Administration. Food standards: amendment of standards of identity for enriched grain products to require addition of folic acid. Federal Register 1996;61:8781–97.
- 4. CDC. Use of dietary supplements containing folic acid among women of childbearing age—United States, 2005. MMWR 2005;54:955–8.
- Ganji V, Kafai MR. Trends in serum folate, RBC folate, and circulating total homocysteine concentrations in the United States: analysis of data from National Health and Nutrition Examination Surveys, 1988– 1994, 1999–2000, and 2001–2002. J Nutr 2006;136:153–8.
- Williams LJ, Rasmussen SA, Flores A, Kirby RS, Edmonds LD. Decline in the prevalence of spina bifida and anencephaly by race/ ethnicity: 1995–2002. Pediatrics 2005;116:580–6.
- Briefel RR, Johnson CL. Secular trends in dietary intake in the United States. Annu Rev Nutr 2004;24:401–31.
- 8. Johnston KE, Tamura T. Folate content in commercial white and whole wheat sandwich breads. J Agric Food Chem 2004;52:6338–40.
- 9. Mojtabai R. Body mass index and serum folate in childbearing age women. Eur J Epidemiol 2004;19:1029–36.
- Food and Drug Administration. Food labeling: health claims and label statements; folate and neural tube defects. Federal Register 1993;58: 53254–95.

[§]NBDPN data are used by *Healthy People 2010* to track NTD prevalence.

Brief Report

Latent Tuberculosis Infection Among Sailors and Civilians Aboard U.S.S. Ronald Reagan — United States, January–July 2006

Crews aboard ships live and work in crowded, enclosed spaces. Historically, large tuberculosis (TB) outbreaks and extensive transmission of Mycobacterium tuberculosis have occurred on U.S. Navy ships (1,2). On July 13, 2006, smearand culture-positive, cavitary, pulmonary TB was diagnosed in a sailor aboard the aircraft carrier U.S.S. Ronald Reagan; the patient, aged 32 years, had a negative human immunodeficiency virus test. The M. tuberculosis strain cultured was susceptible to all first-line TB medications. The sailor was born in the Philippines, had latent tuberculosis infection (LTBI)* diagnosed in 1995 shortly after enlisting in the U.S. Navy, and completed the 6-month daily isoniazid course that was standard treatment at that time (current treatment standard is 9 months). This report describes the contact investigation conducted by the U.S. Navy and CDC and demonstrates the importance of timely diagnosis of TB, identification and treatment of new LTBI, and cooperation among local, state, and federal agencies during large contact investigations.

During January 4–July 6, 2006, U.S.S. Ronald Reagan deployed with approximately 5,000 sailors aboard. Approximately 3,350 sailors were assigned to the ship's company and 1,630 to the air wing.[†] During June 29–July 6, a total of 1,225 family members and friends of sailors (i.e., temporary civilian guests) boarded the ship in Hawaii and sailed to California. Short cruises for civilians are a tradition in the U.S. Navy; this 1-week trip marked the end of deployment for U.S.S. Ronald Reagan and its return to its home port of San Diego. During the cruise, civilians slept in the same quarters as sailors.

The patient was assigned to the air wing of the ship and received the diagnosis of TB on July 13. The next day, the U.S. Navy initiated a contact investigation.

Annual tuberculin skin tests (TSTs) are mandatory for all deployable naval personnel; therefore, documented baseline TST results were available for comparison. Among sailors designated as close contacts of the patient, 12 (4%) of 320 had new positive TST results. The U.S. Navy expanded the contact investigation to include all sailors and civilians who were aboard the ship >48 hours after February 20, 2006, the

estimated start date of the patient's infectious period (*3*). The U.S. Navy contacted CDC for assistance with the civilian contact investigation.

All sailors were screened for TB, and the ship environment was assessed. To prioritize civilians for TB screening, a casecontrol study was conducted among sailors to identify factors associated with a new positive TST result. The patient was interviewed about personal, social, and occupational activities during the ship's deployment. A questionnaire was developed to collect information on potential exposure factors among study participants. A case was defined as a \geq 5-mm increase in TST induration (localized swelling) diameter compared with the most recent TST result in a sailor aboard the U.S.S. Ronald Reagan during January-July 2006. A control was defined as a <5-mm increase in TST induration diameter compared with the most recent TST result in a sailor aboard the ship during the same period. To decrease misclassification of outcome status, all sailors with previous positive TST results were excluded from the study.

No additional TB disease[§] was identified in sailors (4). However, 139 (3%) sailors had new positive TST results (indicating LTBI); all began isoniazid treatment for LTBI. A total of 123 (88%) sailors had TST results that met the case definition and were included in the study; 47 (38%) were members of the ship's company, and 76 (62%) were members of the air wing. A total of 92 (75%) of 123 case-patients and 549 (69%) of 800 controls completed questionnaires. In multivariable analysis, after controlling for other exposure factors, two variables were significantly associated with a new positive TST result: 1) being born outside of the United States (adjusted odds ratio [AOR] = 2.8; 95% confidence interval [CI] = 1.6–5.1; p<0.001) and 2) being a member of the air wing (AOR = 2.9; CI = 1.8–4.6; p<0.001).

The patient and other air-wing sailors slept in an open-bay compartment with 120 bunks arranged in stacks of three; another compartment of the same size for air-wing sailors was adjacent and connected to the patient's compartment. The patient's bunk was approximately 18 feet from an air intake that exhausted directly overboard for odor control. Despite several months of potential exposure in a high-risk setting, results from screening of all sailors suggested limited transmission of *M. tuberculosis* on the ship. Case-control study results indicated that sailors assigned to the air wing were at

^{*} Persons with LTBI have a positive tuberculin skin test result, a normal chest radiograph, and no signs or symptoms of TB disease. Persons with LTBI are asymptomatic, do not feel ill, and cannot spread TB to others.

[†] The U.S.S. Ronald Reagan's air wing includes sailors from eight aircraft squadrons that support carrier flight operations during deployments. The ship's company includes sailors who are permanently assigned to the ship.

[§] Persons with clinical TB disease generally have a positive TST result and other signs and symptoms compatible with TB (e.g., an abnormal chest radiograph) or clinical evidence of current disease. Laboratory criteria for TB disease diagnosis include isolation of *M. tuberculosis* from a clinical specimen or demonstration of *M. tuberculosis* from a clinical specimen by nucleic acid amplification testing or demonstration of acid-fast bacilli in a clinical specimen when a culture has not been or cannot be obtained.

1382	MMWR	January 5, 2007

greatest risk for having a new positive TST result. Sailors assigned to the air wing slept in the same berthing compartment as the patient or in one that was adjacent to the patient. These findings were used to prioritize the contact investigation among civilians.

Thirty-eight male civilians slept in the same berthing compartment as the patient (n = 31) or an adjacent compartment (n = seven). Thirty-six (95%) of the 38 civilians were screened; two (5%) refused screening. Thirty-three (92%) had negative TST results. Two (6%) had known previous positive TST results, and both had clinical evaluations negative for TB. One (3%) civilian aged 70 years had a 15-mm TST result 18 days postexposure; no baseline TST was available for comparison. A second round of TST screening for sailors and civilians at risk for exposure began September 14.

Reported by: Captain F Chapman, MD, Commander, Naval Air Forces, US Pacific Fleet, San Diego; Lieutenant N Martin, MS, Naval Hospital Lemoore, Lemoore; Lieutenant J McDowell, MD, Carrier Air Wing Fourteen, San Diego; Lieutenant Commander T O'Hara, MD, Lieutenant Commander K Carrigan, MD, Navy Environmental and Preventive Medicine Unit Five, San Diego, California. T Wofford, Office of Workforce and Career Development; Div of Tuberculosis Elimination, National Center for HIV, Viral Hepatitis, STDs, and Tuberculosis Prevention (proposed); S Deshpande, PhD, A Buff, MD, EIS officers, CDC.

References

- LaMar JE, Malakooti M. Tuberculosis outbreak investigation of a U.S. Navy amphibious ship crew and the marine expeditionary unit aboard, 1998. Mil Med 2003;168:523–7.
- DiStasio AJ, Trump DH. The investigation of a tuberculosis outbreak in the closed environment of a U.S. Navy ship, 1987. Mil Med 1990; 155:347–51.
- CDC. Guidelines for the investigation of contacts of persons with infectious tuberculosis; recommendations from the National Tuberculosis Controllers Association and CDC. MMWR 2005;54(No. RR-15).
- CDC. Reported tuberculosis in the United States, 2005. Atlanta, GA: US Department of Health and Human Services, CDC; 2006. Available at http://www.cdc.gov/nchstp/tb/surv/surv2005.

Notice to Readers

Tenth Annual Conference on Vaccine Research

CDC and 11 other national and international agencies and organizations will collaborate with the National Foundation for Infectious Diseases to sponsor the Tenth Annual Conference on Vaccine Research: Basic Science, Product Development, and Clinical and Field Studies, to be held April 30–May 2, 2007, at the Marriott Waterfront Hotel, Baltimore, Maryland. The conference has become the largest forum devoted exclusively to the research and development of vaccines and related technologies for the prevention and treatment of disease through immunization, bringing together human and veterinary vaccinology researchers.


Eighteen speakers will participate in various symposia on immune memory, maternal immunization to protect newborns, vaccination of persons who are immunocompromised, host factors, influenza, animal model hosts, and vaccinedevelopment constructs and topics. Two poster and six oral sessions will feature presentations selected through peer review of submitted abstracts.

The deadline for online submission of abstracts is February 2, 2007. Information about the preliminary program, abstract submission, registration, hotel accommodation, and exhibition space is available at http://www.nfid.org/ conferences/vaccine07 and by e-mail (vaccine@nfid.org), fax (301-907-0878), telephone (301-656-0003, ext. 19), and mail (National Foundation for Infectious Diseases, 4733 Bethesda Avenue, Suite 750, Bethesda, MD 20814).

Errata: Vol. 55, No. 50

On page 1355, the third sentence of the first full paragraph should have read: "Among those with non-Hodgkin's lymphoma, however, little difference could be found with respect to their reporting of experiences that might have been associated with increased risk for exposure to Agent Orange."

On page 1375, the title for Figure I should have read: "Selected notifiable disease reports, United States, comparison of provisional 4-week totals December 16, 2006, with historical data."



*Per 1,000 females in age group.

Age of mother is a predictor of maternal and infant health risk. Pregnant teens aged 15–19 years are less likely to receive timely prenatal care and gain appropriate weight and more likely to smoke during pregnancy than pregnant women aged \geq 20 years. These factors are associated with poor birth outcomes. For example, infants born to mothers who smoke during pregnancy are 65% more likely to have low birthweight and 70% more likely to die in infancy than infants born to nonsmokers. In 2004, the overall U.S. birth rate for mothers aged 15–19 years was 41.1 births per 1,000 females in that age group. Among states, rates ranged from 62.6 (Texas) to 18.2 (New Hampshire).

SOURCE: Martin JA, Hamilton BE, Sutton PD, et al. Births: final data for 2004. Natl Vital Stat Rep 2006;55(1). Available at http://www.cdc.gov/nchs/data/nvsr/nvsr55/nvsr55_01.pdf.

TABLE I. Provisional cases of infrequently reported notifiable diseases (<1,000 cases reported during the preceding year) — United States, week ending December 23, 2006 (51st Week)*

	Current	Cum	5-year weekly	Total	cases rer	orted for	previou	s vears	
Disease	week	2006	average [†]	2005	2004	2003	2002	2001	States reporting cases during current week (No.)
Anthrax	_	1		_	_	_	2	23	<u> </u>
Botulism:							-	20	
foodborne	2	15	1	19	16	20	28	39	CA (2)
infant	1	82	2	90	87	76	69	97	WA (1)
other (wound & unspecified)	_	46	1	33	30	33	21	19	
Brucellosis	_	106	3	122	114	104	125	136	
Chancroid	_	28	1	17	30	54	67	38	
Cholera	_	6	0	8	5	2	2	3	
Cyclosporiasis§	1	117	1	716	171	75	156	147	FL (1)
Diphtheria	—	_	—	—	_	1	1	2	
Domestic arboviral diseases ^{§.1} :									
California serogroup	—	7	1	80	112	108	164	128	
eastern equine	—	_	0	21	6	14	10	9	
Powassan	—	_	0	1	1		1	N	
St. Louis	—	3	0	13	12	41	28	79	
western equine	_	_	—	—	_	_	_	_	
Ehrlichiosis [§] :	0	440		700	507	000		001	
human granulocytic	3	446	24	790	537	362	511	261	NY (3)
human monocytic	4 1	403	10	521	338	321	216	142	NY (1), NC (3)
human (other & unspecified) Haemophilus influenzae,**	I	176	1	122	59	44	23	6	NC (1)
invasive disease (age <5 yrs):									
serotype b		8	1	9	19	32	34	_	
nonserotype b	1	81	5	135	135	117	144	_	CT (1)
unknown serotype	4	204	4	217	177	227	153	_	NY (1), PA (1), FL (2)
Hansen disease [§]	_	69	3	88	105	95	96	79	
Hantavirus pulmonary syndrome§	_	31	1	29	24	26	19	8	
Hemolytic uremic syndrome, postdiarrheal§	4	241	6	221	200	178	216	202	NC (1), TX (2), CA (1)
Hepatitis C viral, acute	7	752	41	751	713	1,102	1,835	3,976	MI (2), MN (1), MO (1), KS (1), MD (1), CA (1)
HIV infection, pediatric (age <13 yrs) ^{§,††}	_	52	5	380	436	504	420	543	
Influenza-associated pediatric mortality §.§§	1	41	0	45	_	N	N	N	OH (1)
Listeriosis	7	715	15	892	753	696	665	613	NY (2), MD (2), FL (1), TX (1), WA (1)
Measles ¹¹	—	45	1	66	37	56	44	116	
Meningococcal disease, invasive***:									
A, C, Y, & W-135	4	218	7	297	—	_	—	—	IA (1), FL (1), WA (2)
serogroup B	2	130	5	157	—	_	_	—	FL (1), WA (1)
other serogroup	1	24	0	27	_				FL (1)
Mumps	17	6,299	7	314	258	231	270	266	NY (1), MN (5), KS (4), MD (1), VA (1), WV (2),
		10	0	•	0		0	0	CA (3)
Plague	_	16	0	8	3	1	2	2	
Poliomyelitis, paralytic Psittacosis [§]	_	20	0	1 19	12	12	18	25	
Q fever [§]	_	162	2	139	70	71	61	25 26	
Rabies, human	_	2	2	2	70	2	3	20	
Rubella	_	2	0	11	10	2	18	23	
Rubella, congenital syndrome	_	1	0	1		1	1	23	
SARS-CoV ^{§,†††}	_	_	_			8	N	N	
Smallpox [§]	_	_	_			_	_	_	
Streptococcal toxic-shock syndrome§	_	87	3	129	132	161	118	77	
Streptococcus pneumoniae,§									
invasive disease (age <5 yrs)	15	1,079	28	1,257	1,162	845	513	498	NY (4), MI (1), MN (2), AR (2), OK (2), TX (2), AZ (2)
Syphilis, congenital (age <1 yr)	2	268	9	361	353	413	412	441	AZ (2)
Tetanus	1	22	1	27	34	20	25	37	PA (1)
Toxic-shock syndrome (other than streptococca	al)§ 1	96	3	96	95	133	109	127	CA (1)
Trichinellosis	· —	11	0	19	5	6	14	22	
Tularemia [§]	_	85	3	154	134	129	90	129	
Typhoid fever	4	261	7	324	322	356	321	368	WA (2), CA (2)
Vancomycin-intermediate Staphylococcus aure	eus§ —	3	—	2	—	N	N	N	
Vancomycin-resistant Staphylococcus aureus§	_	—	_	3	1	N	N	N	
Yellow fever	—	—	0	—	—	—	1	—	

Cum: Cumulative year-to-date counts. -: No reported cases. N: Not notifiable.

Incidence data for reporting year 2006 are provisional, whereas data for 2001, 2002, 2003, 2004, and 2005 are finalized.

t Calculated by summing the incidence counts for the current week, the two weeks preceding the current week, and the two weeks following the current week, for a total of 5 preceding years. Additional information is available at http://www.cdc.gov/epo/dphsi/phs/files/5yearweeklyaverage.pdf. 8

Not notifiable in all states.

1 Includes both neuroinvasive and non-neuroinvasive. Updated weekly from reports to the Division of Vector-Borne Infectious Diseases, National Center for Zoonotic, Vector-Borne, and Enteric Diseases (proposed) (ArboNET Surveillance).

Data for *H. influenzae* (all ages, all serotypes) are available in Table II.

†† Updated monthly from reports to the Division of HIV/AIDS Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention (proposed). Implementation of HIV reporting influences the number of cases reported. Pediatric HIV data will not be updated monthly for the remainder of this year due to upgrading of the national HIV/AIDS surveillance data management system. Data for HIV/AIDS are available in Table IV quarterly.

§§ Updated weekly from reports to the Influenza Division, National Center for Immunization and Respiratory Diseases (proposed).

11 No measles cases were reported for the current week. ***

Data for meningococcal disease (all serogroups and unknown serogroups) are available in Table II.

111 Updated weekly from reports to the Division of Viral and Rickettsial Diseases, National Center for Zoonotic, Vector-Borne, and Enteric Diseases (proposed).

(51st Week)*			Chlamyd	iat			Coccio	lioidomy	oosis			Crur	tosporid	iocic	
		Previous Current <u>52 weeks</u> Cum C						vious	0515				/ious	10315	
Reporting area					Cum 2005	Current week	52 w Med	eeks Max	Cum 2006	Cum 2005	Current week	52 w Med	veeks Max	Cum 2006	Cum 2005
United States	8,135	19,357	35,170	934,337	941,275	136	151	1,643	7,953	4,901	32	67	594	5,065	7,677
New England Connecticut Maine [§] Massachusetts New Hampshire Rhode Island [§] Vermont [§]	644 183 	640 173 43 289 39 61 20	1,550 1,214 65 606 71 107 41	33,192 9,937 2,189 15,183 1,989 2,851 1,043	32,222 9,825 2,214 14,235 1,813 3,200 935	N N - - N	0 0 0 0 0 0 0 0	0 0 0 0 0 0 0 0	N N N N	N N - - - N	1 1	3 0 1 1 0 0	39 36 6 14 5 6 5	286 36 44 88 50 14 54	350 79 30 151 38 13 39
Mid. Atlantic New Jersey New York (Upstate) New York City Pennsylvania	1,580 695 561 324	2,409 358 504 716 791	3,696 496 1,727 1,566 1,106	117,717 16,110 24,749 37,789 39,069	116,683 18,852 23,586 38,053 36,192	N N N	0 0 0 0	0 0 0 0	N N N N		4 2	10 0 3 2 4	444 3 441 7 17	575 11 174 111 279	3,401 58 2,924 146 273
E.N. Central Illinois Indiana Michigan Ohio Wisconsin	804 804 	3,131 986 387 658 620 383	12,578 1,697 483 9,888 1,424 517	152,330 49,558 18,820 35,129 30,717 18,106	161,041 49,744 19,756 28,842 42,527 20,172	N N N	1 0 0 0 0	3 0 3 2 0	45 — 39 6 N	11 	 	15 2 1 2 4 5	109 21 18 9 33 53	1,229 174 99 137 346 473	1,624 160 85 112 770 497
W.N. Central lowa Kansas Minnesota Missouri Nebraska [§] North Dakota South Dakota	180 	1,171 157 150 235 436 100 32 51	1,455 225 269 348 614 176 61 116	57,208 7,894 7,027 11,022 21,891 5,191 1,570 2,613	57,675 7,231 7,150 12,035 22,047 4,929 1,624 2,659	N N N N N N N N N N N N N N N N N	0 0 0 0 0 0 0	12 0 12 1 0 0	1 N 1 N N N	4 N 3 1 N N	3 1 2 —	12 1 3 2 1 0 1	77 28 8 22 21 16 4 7	853 175 82 225 184 93 9 85	610 121 40 144 246 28 1 30
S. Atlantic Delaware District of Columbia Florida Georgia Maryland [§] North Carolina South Carolina [§] Virginia [§] West Virginia	1,743 81 876 280 	3,739 68 53 967 700 338 626 338 470 59	4,940 107 137 1,190 2,142 499 1,772 1,452 840 227	183,226 3,551 2,805 48,030 32,856 17,733 32,609 18,983 23,634 3,025	172,481 3,343 3,649 42,402 31,420 18,056 30,768 18,137 21,828 2,878	X X Z Z Z	0 0 0 0 0 0 0 0 0 0	1 0 0 1 0 0 0 0 0	5 N N 5 N N N N N N N N N N N N N N N N N N N	2 N N 2 N N N N	18 	15 0 6 5 0 1 1 0	67 3 32 18 3 11 13 6 3	1,160 15 15 557 258 20 97 125 61 12	758 6 18 345 150 34 92 24 71 18
E.S. Central Alabama [§] Kentucky Mississippi Tennessee [§]	535 63 472	1,420 414 163 365 509	1,951 760 691 807 604	72,150 20,408 8,854 18,341 24,547	68,486 16,721 8,165 20,756 22,844	N N N	0 0 0 0	0 0 0 0	N N N	N N N	2 1 1	3 1 1 0 0	15 12 3 3 5	210 107 40 16 47	228 28 148 3 49
W.S. Central Arkansas Louisiana Oklahoma Texas [§]	378 4 374 	2,176 153 224 242 1,459	3,605 336 607 2,159 1,897	104,636 7,764 12,115 12,659 72,098	107,396 8,353 16,836 11,248 70,959	N N	0 0 0 0	1 0 1 0	1 1 N	N N N	 	4 0 1 2	44 2 9 4 35	327 20 69 41 197	228 6 82 44 96
Mountain Arizona Colorado Idaho [§] Montana [§] Nevada [§] New Mexico [§] Utah Wyoming [§]	457 457 — — — — — —	1,000 354 127 41 47 89 191 94 27	1,632 881 395 191 195 397 339 176 54	49,711 18,692 5,480 2,333 2,459 5,222 9,402 4,815 1,308	62,176 20,816 15,220 2,713 2,205 7,295 8,256 4,509 1,162	87 87 N N 	109 105 0 0 1 0 1 0	452 448 0 0 4 3 3 2	5,376 5,246 N N 54 15 59 2	3,178 3,068 N N 66 20 21 3	1 1 	3 0 1 0 0 0 0 0	38 3 7 26 1 5 3 11	341 25 69 — 134 13 30 20 50	143 11 50 15 23 13 17 11 3
Pacific Alaska California Hawaii Oregon [§] Washington	1,814 	3,344 81 2,663 100 174 340	5,079 152 4,231 136 315 604	164,167 3,844 129,332 4,983 8,608 17,400	163,115 4,203 126,485 5,427 8,850 18,150	49 49 N N N	43 0 43 0 0 0	1,179 0 1,179 0 0 0	2,525 2,525 N N	1,706 	3 - 3 -	1 0 0 1 0	52 1 14 1 7 38	84 4 4 76	335 3 200 1 69 62
American Samoa C.N.M.I. Guam Puerto Rico U.S. Virgin Islands	U U 135	0 0 17 95 5	46 0 18 198 16	U U 4,569 178	U U 841 3,922 196	U U N	0 0 0 0 0	0 0 0 0	U U N	U U N	U U N	0 0 0 0	0 0 0 0 0	U U N	U U N

 TABLE II. Provisional cases of selected notifiable diseases, United States, weeks ending December 23, 2006, and December 24, 2005

 (51st Week)*

C.N.M.I.: Commonwealth of Northern Mariana Islands. U: Unavailable. —: No reported cases. N: Not notifiable. Cum: Cumulative year-to-* Incidence data for reporting year 2006 is provisional. Chlamydia refers to genital infections caused by *Chlamydia trachomatis*. Contains data reported through the National Electronic Disease Surveillance System (NEDSS). Cum: Cumulative year-to-date counts. Med: Median. Max: Maximum.

(51st Week)*			Giardias	s			G	ionorrhe	a		Hae		<i>is influen</i> es, all sei	<i>zae</i> , invas rotypes	sive
	Current		vious veeks	Cum	Cum	Current		vious /eeks	Cum	Cum	Current		vious veeks	Cum	Cum
Reporting area	week	Med	Max	2006	2005	week	Med	Max	2006	2005	week	Med	Max	2006	2005
United States	165	318	1,029	16,624	18,760	2,277	6,562	14,136	324,809	325,457	22	40	142	1,941	2,162
New England Connecticut	7	20 2	75 31	1,145 280	1,637 369	113 46	108 42	288 241	5,625 2,363	5,816 2,509	2	2 0	19 9	143 46	157 46
Maine [†]	5	3	14	181	199	_	2	8	127	140	_	0	4	19	12
Massachusetts New Hampshire	_	9 0	18 9	357 28	714 64	66 1	46 3	86 9	2,409 179	2,503 174	_	1 0	7 2	52 10	75 8
Rhode Island [†] Vermont [†]	2	1 3	25 12	113 186	107 184	_	9 1	19 4	484 63	431 59	_	0 0	7 2	6 10	7 9
Mid. Atlantic	42	63	254	3,240	3,375	328	651	1,014	31,526	33,647	6	8	30	380	422
New Jersey New York (Upstate)	30	8 25	13 227	339 1,258	454 1,185	100	102 121	160 455	4,580 6,128	5,632 6,861	4	0 3	2 27	137	90 115
New York City Pennsylvania	2 10	16 16	29 32	851 792	869 867	128 100	175 225	377 401	9,561 11,257	10,240 10,914	2	2 3	6 8	87 156	80 137
E.N. Central	5	49	93	2,404	3,262	320	1,243	7,047	62,642	65,604	_	5	14	268	363
Illinois Indiana	N	9 0	24 0	464 N	762 N	_	364 161	711 249	18,912 8,285	19,705 7,970	_	0 1	6 10	47 75	122 65
Michigan Ohio	5	14 16	37 32	670 788	779 799	320	262 293	5,880 685	15,104 14,124	11,804 20,337	_	0 2	4	24 91	24 108
Wisconsin	_	9	40	482	922	_	132	172	6,217	5,788	_	0	4	31	44
W.N. Central Iowa	7 1	27 5	260 15	1,720 281	2,255 279	41	369 35	447 62	18,113 1,760	18,382 1,584	2	2 0	15 1	149 2	115
Kansas Minnesota	_	3 1	11 238	200 489	207 1,002	23	40 58	124 105	1,984	2,481 3.437	2	0	2 9	16 79	18 44
Missouri	6	9	28	527	516	_	189	252	9,672	9,298	_	Ō	6	34	34
Nebraska† North Dakota	_	2 0	9 7	114 17	115 19	12	27 2	56 6	1,368 120	1,113 126	_	0 0	2 3	9 9	16 3
South Dakota		2	6	92	117	6	6	15	365	343	_	0	0		_
S. Atlantic Delaware	43	50 0	95 4	2,628 38	2,733 58	685 31	1,617 28	2,334 44	81,550 1,462	76,594 895	6	10 0	24 1	515 1	516
District of Columbia Florida	36	1 20	4 44	62 1.129	54 970	418	35 455	59 547	1,824 22,706	2,111 19,754	3	0 3	2 9	8 159	10 132
Georgia Maryland [†]	4	11 4	28 11	569 216	740 203	109	351 126	1,014 190	16,504 6,461	14,846 6,949	3	2	6 5	99 74	112 73
North Carolina	N	0	0	N	N	_	310	766	16,625	14,786	_	0	9	53	74
South Carolina† Virginia†	3	1 8	7 50	101 476	105 552	127	145 130	704 288	8,545 6,457	8,437 8,058	_	0 1	3 8	34 66	35 53
West Virginia		0	6	37	51		18	43	966	758	—	0	4	21	27
E.S. Central Alabama [†]	5 3	10 6	42 30	555 324	423 194	204 34	576 191	867 313	29,230 9,389	27,604 9,246	_	2 0	7 5	110 33	118 18
Kentucky Mississippi	N	0 0	0 0	<u>N</u>	<u>N</u>	_	61 143	268 435	3,250 7,241	2,871 6,989	_	0 0	1	5 4	13
Tennessee [†]	2	4	12	231	229	170	190	238	9,350	8,498	_	1	4	68	87
W.S. Central Arkansas	6 3	5 2	31 8	295 133	318 82	181	899 81	1,430 142	45,547 4,046	43,956 4,421	2	1 0	15 2	67 7	112 7
Louisiana Oklahoma	3	0 2	5 24	37 125	63 173	6 175	136 87	354 764	7,646 4,797	9,332 4,464	2	0 1	3 14	11 49	37 60
Texas [†]	N	0	0	N	N	_	568	917	29,058	25,739	—	0	0	_	8
Mountain Arizona	6 1	30 3	67 36	1,632 158	1,532 147	81 81	219 92	428 198	11,266 4,604	13,445 4,842	2 2	4 1	8 7	189 85	214 98
Colorado Idaho†	3	9 3	33 12	525 189	527 154	_	42 2	85 15	2,067 139	3,153 116	_	1 0	4 1	49 7	43 5
Montana [†] Nevada [†]	1	2 1	11	108 95	80 113	_	3 25	20 135	186 1,653	144 2,877	_	0 0	0 1	2	
New Mexico [†]	_	1	6	68	89	_	32	65	1,667	1,522	—	0	4	25	32
Utah Wyoming [†]	1	7 1	25 4	451 38	392 30	_	18 2	25 6	834 116	708 83	_	0 0	4 1	17 4	13 9
Pacific	44	58	202	3,005	3,225	324	788	967	39,310	40,409	2	2	15	120	145
Alaska California	24	1 41	17 105	97 2,122	109 2,299	239	10 653	24 834	530 32,496	581 33,620	_	0 0	2 9	9 27	27 56
Hawaii Oregon†	1 9	1 8	4 14	48 391	62 411	_	17 27	26 49	836 1,293	1,010 1,535	2	0 1	1 6	20 62	9 52
Washington	10	7	90	347	344	85	76	142	4,155	3,663	—	0	4	2	1
American Samoa C.N.M.I.	U U	0 0	0 0	U U	U U	U U	0 0	2 0	U U	U U	U U	0 0	0 0	U U	U U
Guam Puerto Rico	_	0	0 12	 84	11 262		5 5	15 16	274	96 357	_	0	1	_	14 4
U.S. Virgin Islands	_	0	0	_		—	0	5	30	45	_	Ő	Ő	_	_

C.N.M.I.: Commonwealth of Northern Mariana Islands. U: Unavailable. —: No reported cases. N: Not notifiable. Cum: Cumulative year-to-* Incidence data for reporting year 2006 is provisional. * Contains data reported through the National Electronic Disease Surveillance System (NEDSS). Cum: Cumulative year-to-date counts. Med: Median. Max: Maximum.

(SIST WEEK)"				Нера	titis (viral,	acute), by ty	/pe								
		Dro	A vious				Prev	B					egionello vious	sis	
	Current		veeks	Cum	Cum	Current	52 w		Cum	Cum	Current		veeks	Cum	Cum
Reporting area	week	Med	Max	2006	2005	week	Med	Max	2006	2005	week	Med	Max	2006	2005
United States	34	65	245	3,227	4,346	44	85	574	4,056	4,764	15	42	127	2,350	2,182
New England Connecticut	1	3 1	20 2	159 41	446 49	_	2 0	8 3	94 30	155 48	_	2 0	12 9	123 54	149 35
Maine [†]	_	0	2	6	8	_	0	2	23	14	_	0	2	10	7
Massachusetts New Hampshire	_	0	6 16	51 37	287 81	_	0 0	5 2	14 13	54 30	_	0 0	4 1	27 1	67 9
Rhode Island [†] Vermont [†]	—	0	4	16	15	_	0	4	10	3	—	0	10	23	21
Mid. Atlantic	5	0 6	2 17	8 344	6 637	6	0 8	1 55	4 412	6 641	 10	0 12	2 47	8 873	10 754
New Jersey	_	1	5	71	154	—	2	8	96	237	_	1	11	96	121
New York (Upstate) New York City	2 1	1 2	14 10	92 116	98 286	4	1 2	43 5	63 89	58 128	7	5 2	30 16	323 135	211 117
Pennsylvania	2	1	5	65	99	2	3	9	164	218	3	5	19	319	305
E.N. Central Illinois	1	6 1	13 4	292 61	373 128	1	8 1	24 7	387 61	559 157	_	8 0	25 3	459 21	451 64
Indiana	_	0	5	29	20	_	0	17	56	40	_	0	4	36	32
Michigan Ohio	1	2 1	6 4	113 52	127 51	1	3 2	6 10	137 125	185 130	_	2 4	11 19	138 228	121 200
Wisconsin	_	1	4	37	47	_	ō	2	8	47	_	0	5	36	34
W.N. Central Iowa	8	2 0	7 2	133 12	120 20	1	3 0	22 3	157 16	275 29	1	1 0	15 3	77 10	98 8
Kansas	_	0	5	27	17	_	0	2	9	30	_	0	2	6	3
Minnesota Missouri	7 1	0 1	7 3	23 44	32 31	1	0 2	13 6	24 84	29 155	1	0 0	11 3	25 22	29 30
Nebraska [†]	—	0 0	2 2	18	19	_	0 0	3 0	21	24	—	0	2	9	5
North Dakota South Dakota	_	0	23	9	1	_	0	1	3	8	_	0	1	5	2 21
S. Atlantic	5	10	29	543	715	22	23	66	1,137	1,401	4	9	19	450	418
Delaware District of Columbia	_	0 0	2 2	12 8	6 6	_	1 0	4 2	46 9	36 12	_	0 0	2 5	12 33	19 13
Florida Georgia	5	4	13 5	213 59	285 123	13	8 3	19 7	412 168	495 201	_2	3 0	9 3	161 24	113 39
Maryland [†]	_	1	6	62	81	1	2	9	148	153	1	2	7	94	111
North Carolina South Carolina [†]	_	0 0	20 3	99 24	84 44	6 1	0 2	23 7	154 81	167 158	1	0 0	5 1	38 5	36 15
Virginia† West Virginia	_	1 0	11 3	60 6	82 4	1	1 0	18 18	68 51	128 51	_	1 0	7 3	67 16	48 24
E.S. Central	2	2	8	126	235		7	20	382	361	_	2	9	105	87
Alabama [†] Kentucky	2	0 0	3 5	20 33	44 24	_	2 1	12 5	138 67	88 67	_	0 0	2 5	13 44	14 32
Mississippi		0	1	9	19	_	1	4	38	53	_	0	2	3	3
Tennessee [†]	_	1	5	64	148	_	2	7	139	153	_	1	7	45	38
W.S. Central Arkansas	_	6 0	77 9	334 38	475 19	1	17 1	315 3	796 50	631 70	_	1 0	32 3	61 3	46 6
Louisiana Oklahoma	_	0 0	4 3	24 9	63 5	1	0 0	5 17	35 73	70 44	_	0 0	2 6	4 7	4 7
Texas [†]	_	5	73	263	388	_	13	295	638	447	_	0	26	47	29
Mountain	6	5	17	264	339	1	3	16	137	188	—	2	8	118	97
Colorado	6	2 1	16 3	165 38	188 48	_	0 1	4 5	9 34	58	_	0	4 2	38 22	25 20
Idaho† Montana†	_	0	2 3	9 11	21 10	1	0 0	2 7	15	16 3	_	0 0	3 1	11 6	4 6
Nevada [†]	_	0	2	11	23	_	0	5	30	50	_	0	2	8	20
New Mexico† Utah	_	0 0	3 2	14 13	27 21	_	0 0	2 5	20 28	20 38	_	0 0	1 6	5 28	4 14
Wyoming [†]	_	0	1	3	1	_	0	1	1	3	_	0	0	_	4
Pacific Alaska	6	17 0	163 0	1,032	1,006 4	12	11 0	61 3	554 9	553 8	_	1 0	9 0	84	82 1
California	5	14	162	922	883	10	8	41	408	371	—	1	9	84	78
Hawaii Oregon†	_	0 1	3 5	13 47	24 45	_	0 1	1 5	6 78	10 100	N	0 0	0 0	N	3 N
Washington	1	1	13	50	50	2	0	18	53	64	_	0	0		_
American Samoa C.N.M.I.	U U	0	0 0	U U	1 U	U U	0 0	0 0	U U		U U	0 0	0 0	U U	U U
Guam Puerto Rico	_	0 0	0	—	2		0 0	0	_	18	_	0	0	—	_
U.S. Virgin Islands	_	0	6 0	32	65	_	0	8 0	32	55 —	_	0	1 0	2	_

C.N.M.I.: Commonwealth of Northern Mariana Islands. U: Unavailable. —: No reported cases. N: Not notifiable. Cum: Cumulative year-to-* Incidence data for reporting year 2006 is provisional. * Contains data reported through the National Electronic Disease Surveillance System (NEDSS). Cum: Cumulative year-to-date counts. Med: Median. Max: Maximum.

(51st Week)*			Lyme dis	ease				Malaria	a		
		Pre	evious				Prev	vious	-		
Departing area	Current		veeks	Cum	Cum	Current	-	eeks	Cum	Cum	
Reporting area	week	Med	Max	2006	2005	week	Med	Max	2006	2005	
United States	114	223	2,153	16,835	21,211	10	26	125	1,245	1,376	
New England Connecticut	24 16	18 9	780 753	2,903 1,687	3,977 1,057	_	1 0	11 3	48 11	75 21	
Maine [†]	6	1	34	287	247	_	0	1	4	5	
Massachusetts	—	0	10 94	33	2,333	—	0 0	3	19 10	39	
New Hampshire Rhode Island [†]	_	4 0	94 93	558 235	250 37	_	0	3 8	3	6 2	
Vermont [†]	2	1	15	103	53	_	Õ	1	1	2	
Mid. Atlantic	67	134	1,176	9,462	12,039	2	6	13	275	354	
New Jersey		23	173	1,918	3,354	_	0	3	28	78	
New York (Upstate) New York City	40	60 1	1,150 18	4,025 164	4,015 399	2	1 3	11 9	48 152	50 189	
Pennsylvania	27	34	231	3,355	4,271	_	1	4	47	37	
E.N. Central	_	9	150	1,444	1,730	_	2	7	138	148	
Illinois	—	0	0	_	127	—	1	5	62	74	
Indiana Michigan	_	0 1	3 5	21	30	_	0 0	3	11	8	
Michigan Ohio	_	1	5 5	54 42	61 57	_	0	2 3	19 28	23 28	
Wisconsin	_	8	146	1,327	1,455	_	0	2	18	15	
W.N. Central	1	6	169	845	944	_	0	32	62	47	
lowa	—	1	8	87	91	_	0	1	2	8	
Kansas Minnesota	1	0 2	2 167	5 729	3 829	_	0 0	2 30	8 39	7 11	
Minnesota Missouri		2	167	12	829	_	0	30	39 6	18	
Nebraska [†]	_	0	2	11	4	_	0	1	5	3	
North Dakota	_	0	3			—	0	1	1	—	
South Dakota	_	0	1	1	2	_	0	1	1		
S. Atlantic Delaware	22	29 7	116 28	1,909 465	2,262 643	3	6 0	14 1	316 5	317 3	
District of Columbia	_	Ó	7	403 59	8	_	0	2	5	11	
Florida	2	1	5	59	46	—	1	4	60	68	
Georgia Maryland†	9	0 12	1 73	7 942	6 1,223	—	1 1	6 5	80 70	49 99	
North Carolina	9	0	73 4	942 30	46	3	0	5 4	31	38	
South Carolina [†]	_	Õ	2	18	21	_	õ	2	10	11	
Virginia [†]	10	4	29	315	252	—	1	9	53	35	
West Virginia		0	44	14	17	_	0	1	2	3	
E.S. Central Alabama†	_	0 0	3 3	36 16	36 3	1	0 0	3 2	25 11	30 6	
Kentucky	_	0	2	7	5	_	0	1	4	10	
Mississippi	—	0	1	1	—		0	1	4	—	
Tennessee [†]	_	0	2	12	28	1	0	2	6	14	
W.S. Central	—	0 0	3 0	19	77	—	1 0	31	84 3	122	
Arkansas Louisiana	_	0	0	_	5 3	_	0	2 1	3 5	6 5	
Oklahoma	_	0	0	_		_	0	2	7	10	
Texas [†]	—	0	3	19	69	—	1	29	69	101	
Mountain	_	0	3	27	21	—	1	9	67	54	
Arizona Colorado	_	0 0	2 1	7 1	8	_	0 0	9 2	23 16	13 25	
Idaho†	_	0	2	7	2	_	0	1	1		
Montana [†]	_	0	0	_	—	—	0	1	2	_	
Nevada† New Mexico†	_	0 0	1 1	3 2	3 3	_	0 0	1	4	4 3	
Utah	_	0	1	6	2	_	0	2	17	7	
Wyoming ⁺	—	0	1	1	3	—	0	0	_	2	
Pacific	—	4	11	190	125	4	4	13	230	229	
Alaska	_	0	1	3	4 90	4	0	4	23	170	
California Hawaii	N	3 0	9 0	169 N	90 N	4	3 0	8 2	154 8	172 18	
Oregon†		0	2	15	21	_	0	2	12	13	
Washington	—	0	3	3	10	—	0	5	33	19	
American Samoa	U	0	0	U	U	U	0	0	U	U	
C.N.M.I. Guam	U	0 0	0	U	U	U	0 0	0 0	U	U	
Puerto Rico	N	0	0	N	N	_	0	1	1	4	
U.S. Virgin Islands	_	0	0	_	_	_	0	0	—	_	

C.N.M.I.: Commonwealth of Northern Mariana Islands. U: Unavailable. —: No reported cases. N: Not notifiable. Cum: Cumulative year-to-* Incidence data for reporting year 2006 is provisional. Contains data reported through the National Electronic Disease Surveillance System (NEDSS). Cum: Cumulative year-to-date counts. Med: Median. Max: Maximum.

(JIST WEEK)					jococcal d	isease, inva									
			All serogr	roups				ogroup u	nknown				Pertus	sis	
	Current		vious veeks	Cum	Cum	Current	Prev 52 w		Cum	Cum	Current		/ious /eeks	Cum	Cum
Reporting area	week	Med	Max	2006	2005	week	Med	Max	2006	2005	week	Med	Max	2006	2005
United States	19	20	85	1,057	1,179	12	12	58	685	725	142	256	2,877	12,867	22,739
New England Connecticut	_	1 0	3 2	44 10	69 14	_	0 0	2 2	28 3	24 1	1	23 1	83 5	1,121 45	1,553 83
Maine [†]	_	0	2	8	2	_	0	1	4	2	_	1	11	111	55
Massachusetts New Hampshire	_	0 0	2 2	15 6	32 12	_	0 0	2 2	15 6	7 12	_	14 2	31 36	594 185	1,140 150
Rhode Island [†] Vermont [†]	_	0 0	1 1	2 3	4 5	_	0 0	0 0	_	2	1	0 2	17 14	70 116	36 89
Mid. Atlantic	2	3	13	163	153	2	2	11	127	116	58	36	137	1,860	1,336
New Jersey	2	0	2 7	16 38	31 42	_	0 0	2 5	16 6	31 14	53	3 16	13 123	185 943	189
New York (Upstate) New York City		1	4	58	25	2	1	4	58	25	_	1	8	64	533 110
Pennsylvania	_	1	4	51	55	_	1	4	47	46	5	13	26	668	504
E.N. Central Illinois	_	2 0	12 4	120 18	155 33	_	1 0	7 4	86 18	122 33	_2	41 9	133 22	2,070 453	3,780 907
Indiana Michigan	_	0	5 3	23 22	18 35	_	0	1 1	8 11	8 18	2	4 11	75 38	231 609	321 315
Ohio	_	1	4	43	44	—	1	3	35	38	_	12	29	609	1,156
Wisconsin		0	2 4	14	25	_	0	2	14	25	_	3	11	168	1,081
W.N. Central Iowa	1 1	1 0	2	65 22	83 17	_	0 0	2 1	22 6	35 1	6	23 5	552 15	1,199 274	3,969 1,096
Kansas Minnesota	_	0 0	1 3	3 16	11 16	_	0 0	1 2	3 6	11 6	_4	6 0	19 485	320 164	530 1,086
Missouri	_	0	2	14	28	_	0	1	2	13	1	6	35	299	642
Nebraska† North Dakota	_	0 0	2 1	6 1	6 1	_	0 0	1 1	4 1	3 1	1	2 0	9 25	96 26	292 143
South Dakota		0	1	3	4		0	0				0	4	20	180
S. Atlantic Delaware	7	4 0	14 1	204 6	213 4	4	2 0	7 1	87 6	97 4	43	17 0	46 1	1,008 3	1,404 15
District of Columbia Florida	7	0 2	1 6	2 80	5 78	4	0 0	1 5	2 29	4 32	9	0 4	2 9	6 210	11 205
Georgia	_	0	3	15	18	_	0	3	15	18	_	0	3	25	48
Maryland† North Carolina	_	0 0	2 11	15 32	22 32	_	0 0	1 3	5 12	5 9	33	2 0	9 22	126 222	211 127
South Carolina [†] Virginia [†]	—	0	2 4	24 21	13 34	_	0	2 1	10 8	8 15	1	3 2	11 27	167 202	403 336
West Virginia	_	0	2	9	7	_	0	0		2	_	0	9	47	48
E.S. Central	1	1	4	49	57 6	1	1 0	4	39	44 3	_	6	28	407	514
Alabama [†] Kentucky	_	0 0	2 2	11 11	18	_	Ō	2 2	8 11	18	_	2 0	19 5	148 55	82 154
Mississippi Tennessee [†]	1	0 0	1 2	4 23	7 26	1	0 0	1 2	4 16	7 16	_	1 3	4 11	42 162	62 216
W.S. Central	_	1	23	58	106	_	0	6	25	29	8	17	360	823	2,363
Arkansas Louisiana	_	0 0	3 2	10 7	15 32	_	0 0	2 1	7 4	3 9	_	1 0	21 1	75 13	300 51
Oklahoma	_	0	4	11	14	—	0	0	—	2	_	0	124	28	3
Texas⁺ Mountain	_	0 1	16 5	30 65	45 89	_	0	4	14 24	15 24	8 5	15 47	215 230	707 2,476	2,009 3,984
Arizona	_	0	3	17	34	_	Ō	2	10	11	4	7	177	473	931
Colorado Idaho†	_	0 0	2 1	20 4	18 6	_	0 0	1 1	2 3	5	_	11 1	40 8	716 85	1,357 218
Montana [†] Nevada [†]	—	0	1	5 4	14	_	0	1 0	2	2	—	2 0	9 9	109 66	584
New Mexico [†]	_	0	1	6	5	_	0	1	3	4	_	2	8	121	50 195
Utah Wyoming [†]	_	0 0	1 2	5 4	12	_	0 0	0 2	4	2	1	13 1	39 8	828 78	597 52
Pacific	8	5	27	289	254	5	5	25	247	234	19	29	1,334	1,903	3,836
Alaska California	3	0 3	1 14	3 176	4 143	3	0 3	1 14	3 176	4 143	_	1 21	15 1,136	64 1,335	158 2,046
Hawaii	_	0	2	10	12	_	0	2	10	7	_	1	6	80	163
Oregon [†] Washington	5	0 0	7 9	63 37	51 44	2	0 0	4 7	44 14	51 29	 19	2 5	8 195	103 321	617 852
American Samoa	U	0	0	_	_	U	0	0	U	U	U	0	0	U	U
C.N.M.I. Guam	U	0 0	0	_	1	U	0 0	0 0	U	U 1	U	0 0	0 0	U	U 2
Puerto Rico	_	0	1	4	7	—	0	1	4	7	_	0	1	2	6
U.S. Virgin Islands	_	0	0	_	—	_	0	0	_	_	_	0	0	_	_

C.N.M.I.: Commonwealth of Northern Mariana Islands. U: Unavailable. —: No reported cases. N: Not notifiable. Cum: Cumulative year-to-* Incidence data for reporting year 2006 is provisional. * Contains data reported through the National Electronic Disease Surveillance System (NEDSS). Cum: Cumulative year-to-date counts. Med: Median. Max: Maximum.

(51st Week)*	, Rabies, animal Previous					,									
			, .	mal		Roc			tted fever	r			almonello	osis	
	Current	52 w		Cum	Cum	Current	Prev 52 w		Cum	Cum	Current		vious veeks	Cum	Cum
Reporting area	week	Med	Max	2006	2005	week	Med	Max	2006	2005	week	Med	Max	2006	2005
United States	13	121	239	6,065	5,696	36	36	246	2,079	1,783	465	754	2,291	41,304	43,134
New England Connecticut	2	12 3	26 14	654 204	687 202	_	0 0	2 0	3	8	_	21 0	487 479	1,757 479	2,109 458
Maine [†]	_	2	8	123	61	Ν	0	0	N	N	_	2	10	120	163
Massachusetts New Hampshire	_	3 1	17 5	178 52	327 13	_	0 0	1 1	1	6 1	_	15 3	53 25	782 208	1,125 175
Rhode Island [†] Vermont [†]	2	0 1	3 5	24 73	29 55	_	0 0	2 0	1	1	_	1 1	17 6	92 76	95 93
Mid. Atlantic	1	27	71	1,578	984	3	1	6	85	97	28	83	272	4,927	5,001
New Jersey	Ň	0	0	Ń	N	_	0	1	7	30	—	14	48	803	949 1,194
New York (Upstate) New York City	1	0	24 5	534 44	555 28	_	0	2 3	5 23	1 7	18	25 23	233 50	1,289 1,205	1,184
Pennsylvania	—	16	56	1,000	401	3	1	3	50	59	10	27	67	1,630	1,674
E.N. Central Illinois	_	2 0	18 7	162 46	172 51	1	0 0	6 2	42 5	41 11	3	100 23	192 56	4,992 1,163	5,615 1,811
Indiana Michigan	_	0 1	2 5	11 47	12 39	1	0 0	1 1	7 4	1 6	3	15 17	67 34	828 945	613 943
Ohio	_	0	9	58	70	_	0	4	25	21	_	23	56	1,282	1,320
Wisconsin	N	0	0	N	N	_	0	1	1	2	_	17	27	774	928
W.N. Central lowa	_	6 1	20 7	306 57	318	_	2 0	14 1	206 5	154 7	27	48 8	109 26	2,614 442	2,532 406
Kansas Minnesota	_	1 0	5 6	82 40	78 68	_	0 0	1 2	1 5	5 2	3 10	7 11	16 60	367 704	365 548
Missouri	—	1	6	67	73	_	2	12	170	128	8	14	35	744	795
Nebraska⁺ North Dakota	_	0 0	0 7	24	 31	_	0 0	5 1	25	7	6	3 0	9 46	197 28	219 40
South Dakota	_	1	4	36	68	—	0	0	_	5	_	3	7	132	159
S. Atlantic Delaware	8	40 0	183 0	2,125	2,057	30	16 0	72 3	1,166 21	941 7	243	212 2	388 10	11,239 144	12,748 124
District of Columbia	_	0	0			_	0	1	1	2		1	4	62	58
Florida Georgia	_	0 5	167 24	171 239	201 251	1	0 1	3 5	23 49	13 85	132	92 33	176 70	4,770 1,715	5,442 1,916
Maryland [†] North Carolina	8	7 9	13 22	318 504	379 456	2 24	1 14	6 65	80 841	75 560	14 78	12 32	29 130	714 1,691	794 1,670
South Carolina [†]	_	3	11	174	222	_	0	5	36	73	_	18	51	990	1,427
Virginia† West Virginia	_	11 2	27 7	601 118	477 71	3	2 0	13 2	112 3	117 9	18 1	20 2	57 19	1,013 140	1,121 196
E.S. Central	1	4	16	253	149	1	6	31	398	288	38	58	153	3,292	2,912
Alabama† Kentucky	1	1 0	8 4	83 28	79 17	1	2 0	11 1	134 3	72 3	21 9	20 8	84 23	1,320 442	711 485
Mississippi Tennessee [†]	_	0 2	2 9	4 138	5 48	_	0 4	1 22	4 257	18 195		12 15	42 32	745 785	893 823
W.S. Central	1	2 11	9 34	569	40 843	_	4	161	119	218	ہ 21	68	922	4,177	623 4,318
Arkansas	1	0	5	32	33	_	0	10	51	130	11	15	47	920	710
Louisiana Oklahoma	_	0 1	0 9	66	78	_	0 0	1 154	5 38	6 52	10	12 8	42 48	812 501	902 400
Texas [†]	—	10	29	471	732	_	0	4	25	30	_	32	839	1,944	2,306
Mountain Arizona	_	3 2	27 10	207 137	270 169	_	0 0	6 6	53 10	34 19	16 10	50 18	88 67	2,515 887	2,389 679
Colorado Idaho†	_	0 0	0 25	25	18 12	_	0 0	1 3	2 14	4 3	3	12 3	30 9	594 174	579 150
Montana [†]	_	0	2	14	15	_	0	2	2	1	2	2	10	129	146
Nevada† New Mexico†	_	0	1 2	2 10	14 10	_	0 0	1 2	3 9	4	_	3 4	20 15	186 233	199 249
Utah	_	0	1	11	15	_	0	2	6 7	3	1	5 0	15	268 44	304
Wyoming [†] Pacific	_	4	2 12	8 211	17 216	- 1	0	1	7	2	89	114	4 426	5,791	83 5,510
Alaska	_	0	4	16	4	—	0	0	_	_	—	1	7	72	59
California Hawaii	_	3 0	11 0	170	204	1	0 0	1 0	5	_	74	88 5	292 16	4,550 259	4,254 288
Oregon [†] Washington	U	0 0	4 0	25 U	8 U	N	0 0	1 0	2 N	2 N	3 12	8 10	16 124	417 493	403 506
American Samoa	U	0	0	U	U	U IN	0	0	U	U	IZ U	0	124	493 U	500
C.N.M.I.	Ŭ	0	Ō	Ŭ	Ŭ	U	0	0	U	U	Ŭ	0	0	U	U
Guam Puerto Rico	_	0 1	0 6	68	70	N	0 0	0 0	N	N	_	0 4	1 35	254	45 655
U.S. Virgin Islands	—	0	0	_	—	_	0	0	—	_	_	0	0	—	_

C.N.M.I.: Commonwealth of Northern Mariana Islands. U: Unavailable. —: No reported cases. N: No U: Unavailable. —: No reported cases. N: Not notifiable. Cum: Cumulative year-to- * Incidence data for reporting year 2006 is provisional. * Contains data reported through the National Electronic Disease Surveillance System (NEDSS). Cum: Cumulative year-to-date counts. Med: Median. Max: Maximum.

(51st Week)*	Chia	a tavin n	roducing	E. coli (S1			61	igollogi			Stropto				
	Snig		vious	<i>E. COII</i> (51	EC) [.]			nigellosi: vious	5		Strepto	Prev		nvasive, g	roup A
Reporting area	Current week		eeks Max	Cum 2006	Cum 2005	Current week		eeks Max	Cum 2006	Cum 2005	Current week		eeks Max	Cum 2006	Cum 2005
United States	32	54	297	3,084	3,205	224	254	1,013	13,422	15,177	24	89	282	4,587	4,451
New England	2	2	109	285	221	_	3	70	230	317	_	3	15	183	276
Connecticut Maine [§]	1	0 0	108 8	108 44	60 29	_	0 0	64 2	64 6	56 15	U	0 0	1 2	U 16	99 14
Massachusetts	1	1 0	9 3	82 26	86 18	_	2	11 2	128 11	191 18	_	2	6 9	101 44	125
New Hampshire Rhode Island [§]	_	0	2	8	7	_	0	3	15	20	—	0	3	8	18 9
Vermont [§]	4	0 5	1 107	2 404	21		0 16	2	6 805	17	6	0	2 43	14 874	11
Mid. Atlantic New Jersey	4	0	3	3	356 76	2	3	72 34	242	1,224 313	_	18 2	8	122	860 178
New York (Upstate) New York City	_	0 0	103 4	10 36	134 17	1	4 5	60 13	228 249	269 410	4	5 2	32 8	300 142	244 167
Pennsylvania	2	2	45	195	129	1	1	6	86	232	2	6	13	310	271
E.N. Central Illinois	_	9 1	56 7	634 83	632 139	_	20 7	38 21	1,014 376	1,168 400	3	13 2	44 11	755 144	889 304
Indiana Michigan	_	1 1	8 6	86 91	71 94	_	2 3	18 8	165 144	173 238	3	2 3	11 12	112 210	99 210
Ohio Wisconsin	_	3	18 39	196 178	169 159	_	3	14 9	192 137	135 222	_	4 1	19 4	237 52	186 90
Wisconsin W.N. Central	10	11	35	646	529	13	36	5 77	1,745	1,754	_	5	57	347	286
lowa Kansas	_	2 0	22 4	139 29	99 54	1	2 2	10 11	121 139	99 268	N	0 1	0 5	N 54	N 40
Minnesota	9	3	27	247	174	6	3	24	243	91	_	0	52	156	110
Missouri Nebraska ^ş	_	0 0	1 8	55	97 64	1 5	9 1	69 14	649 126	1,011 158	_	1 1	5 4	83 33	72 25
North Dakota South Dakota	_	0 0	15 5	49	8 33	_	0 6	18 24	103 364	4 123	_	0 0	5 2	11 10	13 26
S. Atlantic	6	9	39	476	424	63	58	143	3,314	2,442	7	22	44	1,133	919
Delaware District of Columbia	_	0 0	3 1	12 3	9 2	_	0 0	2 2	10 17	11 15	_	0 0	2 2	10 18	6 11
Florida Georgia	4	2 2	29 6	97 84	103 49	51	27 20	76 74	1,587 1,227	1,226 662	6	5 4	16 12	301 235	249 196
Maryland [§] North Carolina	— 11	2	8 7	101 122	75 64	9	2	10 21	124 160	101 195	1	4 0	12 26	197 157	173 124
South Carolina§	—	0	2	10	14	_	1	9	72	104	_	1	6	60	35
Virginia [§] West Virginia	_	0 0	8 5	12	103 5	2 1	2 0	9 2	111 6	126 2	_	2 0	11 6	128 27	99 26
E.S. Central	—	2	12	101	175	28 25	15	81 72	970	1,179 217	1 N	3 0	11	193	174
Alabama [§] Kentucky	_	0	5 12	48 101	29 76	25 1	4	15	464 233	324		0	0 5	N 38	N 34
Mississippi Tennessee [§]	_	0 0	0 4	24	8 62	2	2 2	9 12	101 172	101 537	1	0 3	0 9	155	140
W.S. Central	3	1	52	82	117	56	35	596	1,834	3,640	4	7	58	358	339
Arkansas Louisiana	3	0 0	7 0	39	13 22	4	2 1	9 25	125 141	61 136	_	0 0	5 2	27 9	22
Oklahoma Texas§	7	0 2	17 44	43 124	30 52	4 48	2 29	286 308	135 1,433	651 2,792	2 2	2 4	14 43	100 222	118 199
Mountain	2	5	16	312	311	24	25	87	1,473	964	3	11	77	615	584
Arizona Colorado	2	2 1	13 8	127 102	34 82	10	12 3	35 15	726 233	523 169	2	5 3	57 8	330 134	246 176
Idaho [§] Montana [§]	1	1 0	7 0	83	53 16	_	0 0	3 13	15 64	18 5	1	0 0	2 0	10	3
Nevada [§] New Mexico [§]	_	0	5 1	25 4	25 25	_	1 2	20 15	107 164	64 135	_	0	0 7	68	88
Utah	_	1	14	121	66	_	1	6	81	45	_	1	7	69	66
Wyoming [§] Pacific	5	0 2	3 50	20 144	10 440	14 38	0 37	19 148	83 2,037	5 2,489	_	0 2	1 9	4 129	5 124
Alaska	_	0	0	_	—	_	0	2	9	13	_	0	0	_	—
California Hawaii	_	0 0	18 2	18	164 13	29	30 1	104 4	1,716 43	2,174 34	_	0 2	0 9	129	124
Oregon [§] Washington	5	2 2	13 32	112 126	158 105	9	1 2	34 43	122 147	126 142	N N	0 0	0 0	N N	N N
American Samoa	U	0	0	U	U	U	0	0	U	7	U	0	0	U	U
C.N.M.I. Guam	U	0 0	0 0	U	U	U 	0 0	0 0	U	U 20	U	0 0	0 0	U	U
Puerto Rico U.S. Virgin Islands	_	0 0	0 0	_		_	0 0	2 0	13	9	<u>N</u>	0 0	0 0	<u>N</u>	N

C.N.M.I.: Commonwealth of Northern Mariana Islands. U: Unavailable. —: No reported cases. N: No N: Not notifiable.

Cum: Cumulative year-to-date counts.

Max: Maximum.

Med: Median.

¹ Incidence data for reporting year 2006 is provisional.
 ¹ Incidence data for reporting year 2006 is provisional.
 ¹ Incidence *E. coli* O157:H7; Shiga toxin positive, serogroup non-0157; and Shiga toxin positive, not serogrouped.
 ⁸ Contains data reported through the National Electronic Disease Surveillance System (NEDSS).

(51st Week)*	Strepto			e, invasive	disease										
		Drug r Prev	esistant,	all ages		Sypi	nilis, prin Previ	-	seconda	ry			ella (chic vious	kenpox)	
	Current	52 w	eeks	Cum	Cum	Current	52 we	eks	Cum	Cum	Current	52 v	/eeks	Cum	Cum
Reporting area	week	Med	Max	2006	2005	week	Med	Max	2006	2005	week	Med	Max	2006	2005
United States	34	51	333	2,470	2,547	63	175	334	8,807	8,390	382	854	2,857	41,588	29,608
New England Connecticut	U	0 0	24 7	37 U	231 99	6 5	4 0	17 11	212 58	208 47	20 U	30 0	100 48	1,456 U	5,232 1,689
Maine [†] Massachusetts	_	0	2 5	9	N 102	1	0 2	2 6	8 118	1 122	_	0	20 17	151 94	325 2,198
New Hampshire	_	0	0	_	_	_	0	2	13	15	_	6	47	479	334
Rhode Island [†] Vermont [†]	_	0	11 2	13 15	18 12	_	0 0	2 1	13 2	22 1	20	0 12	0 50	732	686
Mid. Atlantic	5	3	15	176	201	7	21	35	1,099	1,002	97	103	184	4,986	4,897
New Jersey New York (Upstate)	N 5	0 1	0 10	N 68	N 78	3	3 3	8 14	150 145	133 75	_	0 0	0 0	_	_
New York City	U	0	0	U	U	3	10	23	543	595	_	0	0	_	_
Pennsylvania E.N. Central	_	2	9 44	108 577	123 612	1	5	12	261 849	199 906	97	103	184	4,986	4,897
Illinois	_	11 0	44	18	38	4	16 7	39 23	398	510	85	327 1	587 7	14,861 68	6,166 103
Indiana Michigan	_	3 0	21 3	159 18	178 47	4	1 2	5 19	88 115	60 86	85	0 107	475 242	475 4.977	 3,879
Ohio		6	42	382	349	_	3	8	182	210	_	153	420	8,686	1,715
Wisconsin W.N. Central	N	0 1	0 191	N 107	N 45	_	1 5	4 13	66 256	40 249	54	9 30	52 98	655 1,905	469 674
Iowa	Ν	0	0	N	N	_	0	3	19	9	N	0	0	Ń	N
Kansas Minnesota	N	0 0	0 191	N 60	N	_	0 0	3 2	26 32	18 69	9	4 0	27 0	358	_
Missouri Nebraska [†]	—	1	3	42	37	—	3	8 2	158	146 4	45	23 0	82 0	1,387	473
North Dakota	_	0	1 0	1	2 3	_	0 0	1	7 1	1	_	Ō	17	45	65
South Dakota	_	0	3	4	3	_	0	3	13	2	_	1	15	115	136
S. Atlantic Delaware	25	26 0	53 0	1,308	1,102 3	13 3	40 0	186 2	2,059 20	2,125 10	11	91 1	860 6	4,365 64	2,875 33
District of Columbia Florida	 25	0 14	3 36	27 740	17 592	6	2 15	9 23	117 709	113 709	_	0 0	5 0	48	40
Georgia	_	7	29	436	368		6	147	377	498	_	0	0	_	—
Maryland [†] North Carolina	N	0 0	0	N	N	2	5 5	14 17	285 292	307 266	_	0 0	0 0	_	_
South Carolina [†]	N	0	0	N	N	2	1 3	5 17	66 187	82 137	1	20 31	53 812	1,111 1,673	646 1,022
Virginia† West Virginia		1	14	105	122		0	1	6	3	10	27	70	1,469	1,134
E.S. Central	3	2	13	142	186	7	13	26	714	482	14	3	39	226	306
Alabama [†] Kentucky	N	0 0	0 0	<u>N</u>	N 32	4	6 1	19 9	320 71	167 52	14 N	2 0	39 0	224 N	306 N
Mississippi Tennessee [†]	3	0 2	0 13	142	1 153	3	1 5	8 13	77 246	48 215	N	0	1 0	2 N	N
W.S. Central	_	0	5	24	117	8	29	54	1,521	1,227	97	197	1,757	10,990	6,867
Arkansas Louisiana	—	0	3	12	14	7	1 4	6 27	76	52 275	_	14	110	926	49
Oklahoma	N	0	4 0	12 N	103 N	1	1	6	297 74	38	_	1 0	8 0	67	129
Texas [†]	N	0	0	N	N	_	22	34	1,074	862	97	176	1,647	9,997	6,689
Mountain Arizona	1 N	2 0	9 0	98 N	53 N	7 7	8 3	25 16	415 187	416 168	4	59 0	137 0	2,799	2,591
Colorado Idaho†	N N	0	0	N N	N N	—	1 0	3	44 2	46 20	_	30 0	76 0	1,435	1,794
Montana [†]		0	0		1	_	0	1	1	7	4	0	13	33	_
Nevada [†] New Mexico [†]	_	0	0	_	_	_	2 1	12 5	109 62	109 56	_	0 3	0 34	350	212
Utah	1	1	9 4	54 44	26 26	—	0	2	10	10	—	18 1	65	917 64	532
Wyoming [†] Pacific	·	1 0	4	44	20	- 11	35	52	1.682	 1,775	_	0	11 0	64	53
Alaska		0	Ö	_		_	0	4	9	9	_	0	0	_	_
California Hawaii	N	0 0	0 1	N 1	N	2	29 0	43 2	1,450 17	1,564 11	N	0 0	0 0	N	N
Oregon [†] Washington	N N	0 0	0 0	N N	N N	9	0 2	6 10	25 181	39 152	N N	0	0 0	N N	N N
American Samoa		0	0			9 U	2	0	U	152 U	U	0	0	U	U
C.N.M.I.	_	0	0	—	_	Ŭ	0	0	U	U	Ŭ	0	0	Ŭ	U
Guam Puerto Rico	N	0 0	0 0	N	N	3	0 3	0 10	141	3 219	_	3 7	4 47	330	441 715
U.S. Virgin Islands	—	0	0	—	_	—	0	0	—	_	-	0	0	_	

C.N.M.I.: Commonwealth of Northern Mariana Islands. U: Unavailable. —: No reported cases. N: Not notifiable. Cum: Cumulative year-to-* Incidence data for reporting year 2006 is provisional. Contains data reported through the National Electronic Disease Surveillance System (NEDSS). Cum: Cumulative year-to-date counts. Med: Median. Max: Maximum.

(51st Week)*					West Nile	virus diseas	se [†]					
			Veuroinva	sive	westmie	virus uiseas	5C.	No	n-neuroin	vasive		
	_		ious	_					vious	_		
Reporting area	Current week	<u>52 w</u> Med	eeks Max	Cum 2006	Cum 2005		Current week	<u>52 w</u> Med	eeks Max	Cum 2006	Cum 2005	
United States	_	1	176	1,396	1,191		_	1	383	2,459	1,683	
New England	_	0	3	9	9		_	0	2	3	4	
Connecticut Maine [§]	_	0 0	3 0	7	4		_	0 0	1 0	2	2	
Massachusetts	—	0	1	2	4		_	0	1	1	2	
New Hampshire Rhode Island [§]	_	0 0	0 0	_	1		_	0 0	0 0	_	_	
Vermont§	_	0	0	—	—		—	0	0	—	—	
Mid. Atlantic	_	0 0	11 2	26	47 3		—	0 0	4 1	10	22 3	
New Jersey New York (Upstate)	_	0	5	2 8	19		_	0	1	2 3	3 5	
New York City Pennsylvania	_	0 0	4 2	8 8	11 14		_	0 0	2 1	4 1	3 11	
E.N. Central	_	0	43	236	259		_	0	22	99	156	
Illinois	—	0	21	116	137		_	0	19	70	115	
Indiana Michigan	_	0 0	7 10	26 47	11 54		_	0 0	2 1	7 2	12 8	
Ohio	—	0	11	36	46		—	0	3	11	15	
Wisconsin	_	0	2	11	11		_	0	2	9	6	
W.N. Central Iowa	_	0 0	35 3	216 21	169 14		_	0 0	79 4	477 13	463 23	
Kansas Minnesota	_	0 0	3 6	17 30	17 18		_	0 0	3 7	13 35	N 27	
Missouri	—	0	13	47	17		_	0	2	12	13	
Nebraska [§] North Dakota	_	0 0	9 5	43 20	55 12		_	0 0	37 28	212 117	133 74	
South Dakota	_	Ö	7	38	36		—	Õ	22	75	193	
S. Atlantic	—	0 0	2 0	14	34		—	0	4	7	29	
Delaware District of Columbia	_	0	0	_	1 3		_	0 0	0 1	1	1 2	
Florida Georgia	_	0 0	1 1	3 2	10 9		_	0 0	0 3	5	11 11	
Maryland [§]	—	0	2	7	4		_	0	1	1	1	
North Carolina South Carolina [§]	_	0 0	0 1	1	2 5		_	0 0	0 0	_	2	
Virginia§	_	0	0	1	_			0	0		1	
West Virginia E.S. Central	_	0	1 14	ı 114	65		N	0 0	16	N 96	N 38	
Alabama [§]	_	0	2	7	6		_	0	0		4	
Kentucky Mississippi	_	0 0	0 10	5 87	5 39		_	0 0	1 16	1 93	 31	
Tennessee [§]	—	Ő	4	15	15		—	Ő	2	2	3	
W.S. Central	—	0	59	353	157		_	0	26	211	150	
Arkansas Louisiana	_	0 0	4 14	23 89	13		_	0 0	2 9	5 83	15 54	
Oklahoma Texas [§]	_	0 0	6 38	27 214	17 127		_	0 0	4 15	18 105	14 67	
Mountain	_	0	61	342	145		_	0	222	1,321	240	
Arizona	_	0	9	48	52		_	0	12	58	61	
Colorado Idaho§	_	0 0	10 30	63 111	21 3		_	0 0	51 151	269 752	85 10	
Montana [§]	_	0	3 9	12	8		—	0	7	21	17	
Nevada [§] New Mexico [§]	_	0	1	34 3	14 20		_	0	13 1	75 5	17 13	
Utah Wyoming [§]	_	0 0	8 7	56 15	21 6		_	0 0	17 8	101 40	31 6	
Pacific	_	0	, 15	86	306		_	0	45	235	581	
Alaska	—	0	0	_			—	0	0	_	—	
California Hawaii	_	0 0	15 0	79	305		_	0 0	33 0	182	575	
Oregon [§] Washington	_	0	2 0	7	1		_	0	12	50 3	6	
American Samoa	 U	0	0	 U	 U		 U	0	2 0	3 U	 U	
C.N.M.I.	U	0	0	U	U		U	0	0	U	U	
Guam Puerto Rico	_	0 0	0 0	_	_		_	0 0	0 0	_	_	
U.S. Virgin Islands	—	Ő	Ő	—	—		—	Ő	Ő	—	—	

C.N.M.I.: Commonwealth of Northern Mariana Islands.

U: Unavailable. —: No reported cases. N: Not notifiable. Cum: Cumulative year-to-date counts.

* Incidence data for reporting year 2006 is provisional.

¹ Updated weekly from reports to the Division of Vector-Borne Infectious Diseases, National Center for Zoonotic, Vector-Borne, and Enteric Diseases (proposed) (ArboNET Surveillance). [§] Contains data reported through the National Electronic Disease Surveillance System (NEDSS).

Med: Median.

Max: Maximum.

TABLE III. Deaths in 122 U.S. cities.* week ending December 23, 2006 (51st Week)


TABLE III. Deaths	<u>in 122 U.</u> 			ending I y age (ye		ber 23	3, 2006 (51st Week)	All ca	auses. b	y age (ye	ars)			
	All			,			P&I [†]		All		<u>,</u>				P&I [†]
Reporting Area	Ages	<u>></u> 65	45-64	25-44	1-24	<1	Total	Reporting Area	Ages	<u>></u> 65	45-64	25-44	1-24	<1	Total
New England	571	407	108	40	11	5	46	S. Atlantic	1,224	765	293	96	41	28	65
Boston, MA Bridgeport, CT	126 32	90 25	20 4	13 1	2 2	1	14 3	Atlanta, GA Baltimore, MD	138 198	83 102	30 63	16 21	5 10	4 2	6 10
Cambridge, MA	21	18	3				3	Charlotte, NC	106	63	27	8	3	5	9
Fall River, MA	30	24	4	2	_	_	3	Jacksonville, FL	140	89	39	8	1	3	12
Hartford, CT	67	43	14	8	1	1	2	Miami, FL	165	117	25	15	6	2	9
Lowell, MA	29	23	5	—	1	_	5	Norfolk, VA	52	27	16	3	3	3	_
Lynn, MA	7	6	_	1	_	_	3	Richmond, VA	51	30	8	6	5	2	_
New Bedford, MA	24	16	4	3	1	_	2	Savannah, GA	30	20	6	1	2	1	3
New Haven, CT Providence, RI	30 65	19 45	9 11	5	1 2	1 2	4 4	St. Petersburg, FL Tampa, FL	62 196	42 148	17 32	2 10	1 3	3	2 13
Somerville, MA	4	43					-	Washington, D.C.	73	38	25	6		3	
Springfield, MA	48	31	12	5	_	_	1	Wilmington, DE	13	6	5	_	2	_	1
Waterbury, CT	23	16	5	1	1	_	2					60		10	
Worcester, MA	65	47	17	1	—	—	—	E.S. Central Birmingham, AL	919 221	584 148	233 54	60 17	24 1	18 1	46 13
Mid. Atlantic	2,074	1,432	450	118	40	34	145	Chattanooga, TN	78	45	23	5	1	4	3
Albany, NY	46	33	7	3	1	2	1	Knoxville, TN	125	78	35	8	2	2	6
Allentown, PA	22	18	2	1	1		3	Lexington, KY	61	44	13	1	2	1	4
Buffalo, NY	84	62	16	2	1	3	12	Memphis, TN	148	86	45	9	4	4	10
Camden, NJ	34 14	18 6	11 5	2	1 1	2	1 1	Mobile, AL Montgomery, AL	78 57	55 40	18 7	1 6	4	2	3
Elizabeth, NJ Erie, PA	53	о 41	5 10	2 2	_	_	4	Nashville, TN	151	40 88	38	13	2 8	2 4	2 5
Jersey City, NJ	U	Ű	Ŭ	Ū	U	U	Ŭ	,							
New York City, NY	1,114	765	252	63	20	14	56	W.S. Central	1,063	683	254	72	24	30	59
Newark, NJ	22	10	6	2	—	4	—	Austin, TX Baton Rouge, LA	97 40	58 29	26 7	7 4	1	5	7
Paterson, NJ	U	U	U	U	U	U	U	Corpus Christi, TX	64	45	14	3	1	1	3
Philadelphia, PA	268	164	71	24	9	_	25	Dallas. TX	201	104	62	24	4	7	10
Pittsburgh, PA [§] Reading, PA	22 48	15 35	5 11	1	1	1 1	3 3	El Paso, TX	80	62	9	5	3	1	3
Rochester, NY	134	106	19	5	3	1	10	Fort Worth, TX	139	90	38	4	1	6	11
Schenectady, NY	26	22	2	2	_		4	Houston, TX	_U	U	U	U	U	U	U
Scranton, PA	27	22	3	_	1	1	2	Little Rock, AR New Orleans, LA ¹	77 U	45 U	23 U	2 U	2 U	5 U	1 U
Syracuse, NY	110	85	14	5	1	5	13	San Antonio, TX	188	123	42	11	8	4	10
Trenton, NJ	19	11	6	2	_	_	1	Shreveport, LA	65	49	12	2	1	1	6
Utica, NY Yonkers, NY	14 17	8 11	5 5	1	_	_	2 4	Tulsa, OK	112	78	21	10	3	_	8
				-				Mountain	1,126	764	213	90	34	25	71
E.N. Central Akron, OH	1,855 44	1,256 33	412 7	109 2	40 1	37 1	122 4	Albuquerque, NM	169	128	26	9	6	—	8
Canton, OH	51	37	10	3	_	1	4	Boise, ID	43	28	8	2	5	_	5
Chicago, IL	177	102	50	17	3	4	8	Colorado Springs, CO	60	38	16	5	1	_	2
Cincinnati, OH	89	60	21	3	3	2	12	Denver, CO Las Vegas, NV	65 317	44 193	12 71	5 38	1 6	3 9	2 29
Cleveland, OH	257	187	53	7	5	5	9	Ogden, UT	27	21	3	2	1		29
Columbus, OH	224	151	60	11		2	15	Phoenix, AZ	156	99	33	11	5	8	6
Dayton, OH Detroit, MI	140 96	102 54	22 29	7 9	3 3	6 1	8 7	Pueblo, CO	25	18	4	3	_	_	1
Evansville, IN	29	24	4		1	_	5	Salt Like City, UT	116	77	21	9	6	3	8
Fort Wayne, IN	87	67	10	7	2	1	10	Tucson, AZ	148	118	19	6	3	2	8
Gary, IN	13	6	5	1	1	—	1	Pacific	1,092	736	243	70	22	19	66
Grand Rapids, MI	55	34	13	.2	3	3	5	Berkeley, CA	18	15	1			1	2
Indianapolis, IN	205	131	46	17	8	3	12	Fresno, CA	U	U	U	U	U	U	U
Lansing, MI Milwaukee, WI	U 67	U 40	U 17	U 10	U	0	U 1	Glendale, CA Honolulu, HI	U 54	U 37	U 13	U 4	U	<u> </u>	U 3
Peoria, IL	39	27	9	3	_	_	1	Long Beach, CA	63	42	13	3	3	1	3
Rockford, IL	49	38	5	2	1	3	4	Los Angeles, CA	Ŭ	U	U	Ŭ	Ŭ	Ů	Ŭ
South Bend, IN	64	43	13	4	2	2	2	Pasadena, CA	U	U	U	U	U	U	U
Toledo, OH	96	65	26	1	2	2	9	Portland, OR	124	79	31	10	2	2	3
Youngstown, OH	73	55	12	3	2	1	5	Sacramento, CA	208	130	53	16	5	4	16
W.N. Central	545	329	151	38	14	13	21	San Diego, CA San Francisco, CA	155 U	110 U	26 U	11 U	3 U	4 U	10 U
Des Moines, IA	U	U	U	U	U	U	U	San Jose, CA	193	137	40	9	3	4	17
Duluth, MN	36	31	5	_	—	—	2	Santa Cruz, CA	24	18	40	2	_	_	2
Kansas City, KS	31	23	6	2		3	1	Seattle, WA	100	66	20	8	5	1	7
Kansas City, MO Lincoln. NE	106 39	70 26	27 7	3 3	3 2	3	2 4	Spokane, WA	50	36	10	2	—	2	_
Minneapolis, MN	39 72	37	22	8		5	4	Tacoma, WA	103	66	31	5	1	_	3
Omaha, NE	Ű	Ű	U	Ŭ	U	Ŭ	Ū	Total	10,469**	6,956	2,357	693	250	209	641
St. Louis, MO	105	49	40	8	5	3	7								
St. Paul, MN	64	35	20	6	3	—	3								
Wichita, KS	92	58	24	8	1	1	_								

U: Unavailable.

U: Unavailable. —:No reported cases. Mortality data in this table are voluntarily reported from 122 cities in the United States, most of which have populations of ≥100,000. A death is reported by the place of its occurrence and by the week that the death certificate was filed. Fetal deaths are not included. [†] Pneumonia and influenza.

¹Because of changes in reporting methods in this Pennsylvania city, these numbers are partial counts for the current week. Complete counts will be available in 4 to 6 weeks. ¹Because of Hurricane Katrina, weekly reporting of deaths has been temporarily disrupted. ** Total includes unknown ages.

FIGURE I. Selected notifiable disease reports, United States, comparison of provisional 4-week totals December 23, 2006, with historical data



Beyond historical limits

* No rubella cases were reported for the current 4-week period yielding a ratio for week 51 of zero (0).
[†] Ratio of current 4-week total to mean of 15 4-week totals (from previous, comparable, and subsequent 4-week periods for the past 5 years). The point where the hatched area begins is based on the mean and two standard deviations of these 4-week totals.

Notifiable Disease Data Team and 122 Cities Mortality Data Team Patsy A. Hall Deborah A. Adams Rosaline Dhara Willie J. Anderson Vernitta Love Lenee Blanton Pearl C. Sharp

1396

MMWR

TABLE I. Provisional cases of infrequently reported notifiable diseases (<1,000 cases reported during the preceding year) — United States, week ending December 30, 2006 (52nd Week)*

	Current	Cum	5-year weekly	Total o	cases rep	orted for	previou	s vears	
Disease	week	2006	average [†]	2005	2004	2003	2002	2001	States reporting cases during current week (No.)
Anthrax	_	1		_	_	_	2	23	
Botulism:							-	20	
foodborne	_	15	1	19	16	20	28	39	
infant	_	83	2	90	87	76	69	97	
other (wound & unspecified)	_	46	1	33	30	33	21	19	
Brucellosis	_	107	3	122	114	104	125	136	
Chancroid	_	28	1	17	30	54	67	38	
Cholera	_	6	0	8	5	2	2	3	
Cyclosporiasis§	1	118	1	716	171	75	156	147	FL (1)
Diphtheria	_	_	_	_	_	1	1	2	
Domestic arboviral diseases ^{§,1} :									
California serogroup	_	63	1	80	112	108	164	128	
eastern equine	—	7	0	21	6	14	10	9	
Powassan	_	1	0	1	1	_	1	N	
St. Louis	—	9	0	13	12	41	28	79	
western equine	_	_	_	_	_	—	—	—	
Ehrlichiosis [§] :									
human granulocytic	2	453	21	790	537	362	511	261	NY (1), AL (1)
human monocytic	1	407	9	521	338	321	216	142	AL (1)
human (other & unspecified)	—	189	1	122	59	44	23	6	
Haemophilus influenzae,**									
invasive disease (age <5 yrs):									
serotype b	—	8	1	9	19	32	34	_	
nonserotype b		82	5	135	135	117	144	—	
unknown serotype	4	<mark>210</mark>	4	217	177	227	153		SC (1), GA (1), FL (1), UT (1)
Hansen disease [§]	_	70	3	88	105	95	96	79	
Hantavirus pulmonary syndromes	_	33	0	29	24	26	19	8	
Hemolytic uremic syndrome, postdiarrheal [§]	6	248	6	221	200	178	216	202	NE (1), FL (2), TX (1), AZ (2)
Hepatitis C viral, acute	2	767	40	751	713	1,102	1,835	3,976	NY (1), MO (1)
HIV infection, pediatric (age <13 yrs) ^{§,††}	—	52	4	380	436	504	420	543	
Influenza-associated pediatric mortality §.§§	_	41	0	45		N	N	N	
Listeriosis	8	726	15	892	753	696	665	613	OH (1), MD (1), GA (1), FL (3), WA (2)
	_	45	1	66	37	56	44	116	
Meningococcal disease, invasive***:		010	7	007					
A, C, Y, & W-135	2	219 132	5	297 157	_	_	_	_	TN(1) N(A(1))
serogroup B	2		5 0		_	_	_	_	TN (1), WA (1)
other serogroup	8	24	6	27 314		001	270		
Mumps	<u> </u>	6,339 16	0	314	258 3	231	270	266 2	PA (1), OH (2), FL (1), AL (4)
Plague Poliomyelitis, paralytic				0 1		1			
Psittacosis [§]	_	20	0	19	12	12	18	25	
Q fever [§]	3	165	2	139	70	71	61	25	MD (1), VA (1), FL (1)
Rabies, human	_	2		2	70	2	3	1	
Rubella		8	0	11	10	7	18	23	
Rubella, congenital syndrome	_	1	0	1		1	1	3	
SARS-CoV ^{§,†††}	_	_	_	_	_	8	Ň	Ň	
Smallpox [§]	_	_	_	_	_	_		_	
Streptococcal toxic-shock syndrome [§]	1	90	3	129	132	161	118	77	OH (1)
Streptococcus pneumoniae,§		00	0	120	102	101	110		
invasive disease (age <5 yrs)	13	1,110	26	1,257	1,162	845	513	498	NY (1), OH (3), MI (1), MD (4), AR (1), NM (1), AZ (2)
Syphilis, congenital (age <1 yr)		267	9	361	353	413	412	441	
Tetanus	_	22	1	27	34	20	25	37	
Toxic-shock syndrome (other than streptococca	al) [§] 2	98	3	96	95	133	109	127	OH (1), CO (1)
Trichinellosis		11	0	19	5	6	14	22	
Tularemia§	1	86	3	154	134	129	90	129	NE (1)
Typhoid fever	1	264	6	324	322	356	321	368	OH (1)
Vancomycin-intermediate Staphylococcus aure		2	_	2		N	N	N	/
Vancomycin-resistant <i>Staphylococcus aureus</i> [§]	_	_	_	3	1	N	N	N	
Yellow fever		_	0	_	_	_	1	_	

-: No reported cases. N: Not notifiable. Cum: Cumulative year-to-date counts.

* Incidence data for reporting year 2006 are provisional, whereas data for 2001, 2002, 2003, 2004, and 2005 are finalized.

[†] Calculated by summing the incidence counts for the current week, the two weeks preceding the current week, and the two weeks following the current week, for a total of 5 preceding years. Additional information is available at http://www.cdc.gov/epo/dphsi/phs/files/5yearweeklyaverage.pdf.

§ Not notifiable in all states.

Includes both neuroinvasive and non-neuroinvasive. Updated weekly from reports to the Division of Vector-Borne Infectious Diseases, National Center for Zoonotic, Vector-Borne, and Enteric Diseases (proposed) (ArboNET Surveillance).

* Data for H. influenzae (all ages, all serotypes) are available in Table II.

⁺⁺⁺ Updated monthly from reports to the Division of HIV/AIDS Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention (proposed). Implementation of HIV reporting influences the number of cases reported. Pediatric HIV data will not be updated monthly for the remainder of this year due to upgrading of the national HIV/AIDS surveillance data management system. Data for HIV/AIDS are available in Table IV quarterly.

§§ Updated weekly from reports to the Influenza Division, National Center for Immunization and Respiratory Diseases (proposed).

No measles cases were reported for the current week.

^{***} Data for meningococcal disease (all serogroups and unknown serogroups) are available in Table II.

ttt Updated weekly from reports to the Division of Viral and Rickettsial Diseases, National Center for Zoonotic, Vector-Borne, and Enteric Diseases (proposed).

(52nd Week)*			Chlamyd	io†			Coooid	loidomu				Craw	tooporid	liagia	
		Pre	vious	la				lioidomy ious	COSIS				otosporid vious	liosis	
Dementing	Current	52 v	veeks	Cum	Cum	Current	52 w	eeks	Cum	Cum	Current	52 v	/eeks	Cum	Cum
Reporting area United States	week 5,900	Med 19,150	Max 35,170	2006 942,024	2005 976,445	week 84	Med 151	Max 1,643	2006 8,071	2005 6,544	week 30	Med 65	Max 594	2006 5,140	2005 8,271
New England Connecticut Maine [§] Massachusetts New Hampshire Rhode Island [§] Vermont [§]	5,500 500 51 334 1 81 33	571 96 43 289 39 61 20	1,550 1,214 65 605 71 107 41	29,942 6,092 2,292 15,504 2,001 2,977 1,076	33,772 11,039 2,254 14,411 1,842 3,269 957			0 0 0 0 0 0 0 0 0	N N N N	0,344 — N — — — — N		3 0 1 1 0 0	39 36 6 14 5 6 5	286 36 44 88 50 14 54	364 84 30 152 40 19 39
Mid. Atlantic New Jersey New York (Upstate) New York City Pennsylvania	743 	2,409 354 504 695 790	3,696 496 1,727 1,566 1,106	119,267 16,110 25,146 37,789 40,222	120,379 19,152 25,313 38,653 37,261	N N N N	0 0 0 0	0 0 0 0 0	N N N N	N N N N	2 1 1	10 0 3 2 4	444 3 441 7 17	584 11 176 114 283	3,845 58 3,365 148 274
E.N. Central Illinois Indiana Michigan Ohio Wisconsin	1,379 436 — 857 56 30	3,116 980 387 662 620 382	12,578 1,408 483 9,888 1,424 518	154,181 49,472 19,163 36,264 30,915 18,367	173,619 50,559 20,063 38,730 43,806 20,461	N N N	1 0 1 0	3 0 3 2 0	47 — 41 6 N	11 	4 _4	16 2 1 2 4 5	109 21 18 9 33 53	1,254 174 99 139 351 491	1,637 160 94 112 774 497
W.N. Central lowa Kansas Minnesota Missouri Nebraska [§] North Dakota South Dakota	210 71 133 6 	1,171 159 150 235 441 100 33 51	1,455 225 269 348 615 176 64 116	58,405 8,187 7,027 11,022 22,716 5,191 1,649 2,613	58,835 7,390 7,419 12,189 22,371 5,098 1,667 2,701	N N N N N N N N N N N N N N N N N	0 0 0 0 0 0 0 0	12 0 12 1 0 0	1 N 1 N N N	16 N 15 1 N N N		12 1 3 2 1 0 1	77 28 8 22 21 16 4 7	856 175 82 225 185 94 9 86	639 122 40 166 246 29 5 31
S. Atlantic Delaware District of Columbia Florida Georgia Maryland [§] North Carolina South Carolina [§] Virginia [§] West Virginia	1,366 64 639 5 314 	3,782 68 55 975 700 339 626 338 470 58	4,977 107 139 1,181 2,142 500 1,772 1,452 840 227	186,804 3,615 2,905 48,829 34,670 18,093 32,609 19,356 23,634 3,093	177,386 3,392 3,678 43,372 33,562 18,291 31,183 18,296 22,668 2,944	X X X Z Z Z Z	0 0 0 0 0 0 0 0 0 0	1 0 0 0 1 0 0 0 0	5 N N 5 N N N N N N	2 N N 2 N N N N	22 20 2 2 	16 0 7 4 0 1 1 0	69 3 32 14 3 11 13 6 3	1,190 15 15 577 265 20 99 126 61 12	774 6 18 350 152 34 92 24 77 21
E.S. Central Alabama [§] Kentucky Mississippi Tennessee [§]	549 294 255	1,420 409 163 365 508	1,951 760 691 807 604	73,188 20,408 8,940 18,976 24,864	69,812 17,109 8,351 21,268 23,084	N N N	0 0 0 0	0 0 0 0	N N N	N N N	 	3 1 1 0 1	15 12 3 3 5	213 110 40 16 47	230 29 149 3 49
W.S. Central Arkansas Louisiana Oklahoma Texas [§]	103 103 — —	2,176 154 222 243 1,459	3,605 336 607 2,159 1,897	104,977 8,105 12,115 12,659 72,098	111,001 8,507 17,227 13,407 71,860	 N	0 0 0 0	1 0 1 0 0	1 1 N N	N N N	 	4 0 1 2	44 2 9 4 35	327 20 69 41 197	252 8 83 46 115
Mountain Arizona Colorado Idaho [§] Montana [§] Nevada [§] New Mexico [§] Utah Wyoming [§]	643 436 207 — — — — — — —	992 359 110 40 47 87 191 94 26	1,632 881 254 191 195 397 339 178 54	50,496 19,128 5,822 2,333 2,459 5,222 9,402 4,822 1,308	63,447 21,264 15,432 2,799 2,400 7,321 8,456 4,602 1,173	84 84 N N 	109 105 0 0 1 0 1 0	452 448 0 0 4 3 3 2	5,492 5,360 N N 54 15 61 2	3,630 3,516 N N 66 20 23 5	2 1 1	3 0 1 0 0 0 0 0	38 3 7 0 26 1 5 3 11	345 27 69 134 13 31 20 51	143 11 50 15 23 13 17 11 3
Pacific Alaska California Hawaii Oregon [§] Washington	407 25 — — 382	3,344 81 2,663 100 170 348	5,079 152 4,231 136 309 604	164,764 3,890 129,332 5,152 8,608 17,782	168,194 4,355 130,716 5,489 9,018 18,616	 	43 0 43 0 0 0	1,179 0 1,179 0 0 0	2,525 2,525 N N	2,885 2,885 N N	 	1 0 0 1 0	52 1 14 1 7 38	85 4 4 77 —	387 3 214 1 69 100
American Samoa C.N.M.I. Guam Puerto Rico U.S. Virgin Islands	U U —	0 9 95 5	46 0 18 198 16	U U 4,571 178	U U 859 3,988 196	U U N	0 0 0 0	0 0 0 0	U U N	U U N	U U N	0 0 0 0	0 0 0 0	U U N	U U N

C.N.M.I.: Commonwealth of Northern Mariana Islands. U: Unavailable. —: No reported cases. N: Not notifiable. Cum: Cumulative year-to-* Incidence data for reporting year 2006 is provisional. * Chlamydia refers to genital infections caused by *Chlamydia trachomatis*. § Contains data reported through the National Electronic Disease Surveillance System (NEDSS). Cum: Cumulative year-to-date counts. Med: Median. Max: Maximum.

1398

MMWR

			Giardias	s			G	onorrhe	a		Hae		i <i>s influen</i> es, all sei	izae, invas rotypes	sive .
			vious			-		/ious				Pre	vious		
Reporting area	Current week	52 w Med	eeks Max	Cum 2006	Cum 2005	Current week	<u>52 w</u> Med	veeks Max	Cum 2006	Cum 2005	Current week	52 v Med	veeks Max	Cum 2006	Cum 2005
United States	149	304	1,029	16,919	19,789	1,856	6,512	14,136	327,541	339,593	25	39	142	<mark>1,982</mark>	2,304
New England	5	20	75	1,153	1,712	55	95	288	4,753	6,104	—	2	19	143	176
Connecticut Maine [†]	2	2 3	31 14	280 183	400 203	4	22 2	241 8	1,429 135	2,750 142	_	0 0	9 4	46 19	55 12
Massachusetts	_	9 0	18 9	357 28	724 66	45 1	46 3	86 9	2,444 180	2,537 177	_	1 0	7 2	52 10	77 9
New Hampshire Rhode Island [†]	_	1	25	113	132	2	9	19	499	438	_	0	7	6	14
Vermont [†]	3	3	12	192	187	3	1	4	66	60	—	0	2	10	9
Mid. Atlantic New Jersev	34	62 8	254 13	3,292 339	3,629 457	198	645 102	1,014 160	31,840 4,580	34,661 5,722	3	8 0	30 2	386	452 92
New York (Upstate)	24	25	227	1,282	1,412	94	119	455	6,222	7,316	2	3	27	139	142
New York City Pennsylvania	1 9	16 15	29 32	867 804	873 887	104	174 226	377 401	9,561 11,477	10,401 11,222	1	2 3	6 8	90 157	80 138
E.N. Central	9	49	93	2,465	3,310	481	1,242	7,047	62,964	72,651	1	5	14	271	377
Illinois Indiana	N	9 0	24 0	464 N	772 N	140	356 159	520 249	18,529 8,408	20,019 8,094	_	0 1	6 10	47 75	124 71
Michigan	2	14	38	693	783	302	262	5,880	15,508	17,684	_	0	5	26	24
Ohio Wisconsin	7	15 9	32 40	800 508	817 938	27 12	287 132	676 172	14,223 6,296	20,985 5,869	1	2 0	6 4	92 31	110 48
W.N. Central	8	27	260	1,733	2,515	91	369	447	18,591	18,785	4	2	15	154	130
Iowa Kansas	—	5 3	15 11	281 200	280 213	21	36 40	62 124	1,837 1,984	1,606 2,605	_	0 0	1 2	2 16	18
Minnesota	_	1	238	489	1,240	_	58	105	2,844	3,482	_	0	9	79	53
Missouri Nebraska†	5 3	9 2	28 9	533 117	522 116	70	192 27	252 56	10,069 1,368	9,455 1,158	3 1	0 0	6 2	38 10	37 16
North Dakota	_	0	7	17	26	_	2	6	124	128	_	0	3	9	6
South Dakota	_	2	6	96	118	_	6	15	365	351	_	0	0		
S. Atlantic Delaware	44	50 0	95 4	2,703 38	2,828 58	546 23	1,614 28	2,334 44	83,214 1,485	78,928 913	12	10 0	24 1	530 1	540
District of Columbia	39	1 20	4 44	62 1,169	56 987	266	35 460	59 551	1,875 23,057	2,146 20,225	8	0 3	2 9	8 167	10 140
Florida Georgia		11	26	592	987 754	200	350	1,014	17,439	15,860	1	2	5	107	113
Maryland† North Carolina	1 N	4 0	11 0	221 N	210 N	97	125 310	190 766	6,565 16,625	7,035 15,072	_2	1 0	5 9	77 53	78 74
South Carolina [†]	3	1	7	105	106	154	145	704	8,717	8,561	1	1	3	36	35
Virginia† West Virginia	1	8 0	50 6	479 37	602 55	3	128 19	288 41	6,457 994	8,346 770	_	1 0	8 4	66 21	61 29
E.S. Central	12	10	42	579	433	242	576	867	29,638	28,117	1	2	7	112	120
Alabama [†] Kentucky	11 N	6 0	30 0	347 N	200 N	_	190 61	313 268	9,389 3,277	9,406 2,935	_	0 0	5 1	34 5	18 14
Mississippi	_	0	0	_	—	133	143	435	7,500	7,171	_	0	1	4	_
Tennessee [†]	1	4	12	232	233	109	190	238	9,472	8,605	1	1	4	69	88
W.S. Central Arkansas	4 4	6 2	31 8	301 137	349 88	48 48	899 81	1,430 142	45,718 4,217	45,386 4,476	_	1 0	15 2	<mark>67</mark> 7	127 7
Louisiana	_	0	5	39 125	64	_	133	354	7,646	9,572	_	0	3	11	38
Oklahoma Texas†	N	2 0	24 0	125 N	197 N	_	88 568	764 917	4,797 29,058	5,228 26,110	_	1 0	14 0	49	74 8
Mountain	21	30	68	1,672	1,586	110	219	428	11,413	13,698	4	4	9	198	222
Arizona Colorado	1 8	3 9	36 33	160 533	183 534	82 28	92 42	198 85	4,686 2,131	4,951 3,224	_2	1	7 4	87 49	105 43
Idaho†	_	3	12	189	155	_	2	15	139	119	—	0	1	7	5
Montana [†] Nevada [†]	_	2 1	11 9	108 95	81 113	_	3 23	20 135	186 1,653	158 2,880	_	0 0	0 1	2	15
New Mexico [†] Utah	12	1 7	6 25	75 474	91 398	_	32 17	65 25	1,667 835	1,552 727	2	0 0	2 4	28 21	32 13
Wyoming [†]		1	4	38	31	_	2	6	116	87		0	1	4	9
Pacific	12	58	202	3,021	3,427	85	786	967	39,410	41,263	_	2	15	121	160
Alaska California	1	1 41	17 105	98 2,122	110 2,404	4	10 652	24 834	533 32,496	600 34,338	_	0 0	2 9	9 27	27 65
Hawaii	2 6	1	4	52 399	63 416	_	17 27	26 49	852 1,293	1,024	_	0	1 6	21 62	9 54
Oregon [†] Washington	3	8 7	90	399 350	416	81	76	49 142	4,236	1,562 3,739	_	0	6 4	62 2	54
American Samoa	U	0	0	U	U	U	0	2	U	U	U	0	0	U	U
C.N.M.I. Guam	U	0	0	U	U 11	U	0 8	0 15	U	U 111	U	0 1	0 1	U	U 15
Puerto Rico	—	1	12	84	274	_	5	16	274	359	—	0	0	—	4
U.S. Virgin Islands	_	0	0	_	_	_	0	5	30	45	_	0	0	_	

TABLE II. (Continued) Provisional cases of selected notifiable diseases, United States, weeks ending December 30, 2006, and December 31, 2005 (52nd Week)*

C.N.M.I.: Commonwealth of Northern Mariana Islands. U: Unavailable. —: No reported cases. N: No N: Not notifiable. Cum: Cumulative year-to-date counts. Med: Median. Max: Maximum.

⁺ Incidence data for reporting year 2006 is provisional. ⁺ Contains data reported through the National Electronic Disease Surveillance System (NEDSS).

(52nd week)*				Нера	titis (viral,	acute), by ty	/pe								
			Α					В					gionello	sis	
	Current		vious veeks	Cum	Cum	Current	Previ 52 we		Cum	Cum	Current		vious /eeks	Cum	Cum
Reporting area	week	Med	Max	2006	2005	week	Med	Max	2006	2005	week	Med	Max	2006	2005
United States	16	64	245	3,263	4,591	31	84	574	4,114	5,338	28	43	127	2,409	2,309
New England Connecticut	2 2	3 1	20 2	161 43	454 51	1	2 0	8 3	94 30	161 50	2	2 0	12 9	125 56	159 35
Maine [†]		0	2	6	9	_	0	2	23	14	_	0	2	10	7
Massachusetts New Hampshire	_	0 0	6 16	51 37	287 82	1	0	5 1	14 13	56 30	_	0 0	4 1	27 1	67 9
Rhode Island [†] Vermont [†]	_	0 0	4 2	16 8	19 6	_	0 0	4 1	10 4	5 6	_	0 0	10 2	23 8	31 10
Mid. Atlantic	2	6	17	347	651	3	8	55	416	696	6	12	48	882	789
New Jersey New York (Upstate)	_	1	5	71	154	—	2	8	96	239	3	1	11	96	121
New York (Upstate)	1	1 2	14 10	93 117	112 286	1	1 2	43 5	64 90	101 132	_	6 2	30 16	326 137	240 119
Pennsylvania	1	1	5	66	99	2	3	9	166	224	3	5	19	323	309
E.N. Central Illinois	1	6 1	13 4	301 61	380 130	1	7 1	24 7	388 61	583 157	_2	8 0	26 3	479 21	463 66
Indiana Michigan	1	0 2	5 7	29 121	23 129	1	0 3	17 6	56 137	57 186	_	0 3	4 11	36 150	33 122
Ohio	_	1	4	52	51	_	2	10	126	136	2	3	19	230	206
Wisconsin	_	1	4	38	47	—	0	2	8	47	_	0	5	42	36
W.N. Central Iowa	_	2 0	8 2	133 12	126 22	_	3 0	22 3	157 16	297 32	_	1 0	15 3	77 10	106 8
Kansas Minnesota	_	0 0	5 7	27 23	17 33	_	0	2 13	9 24	32 42	_	0 0	2 11	6 25	4 34
Missouri	—	1	3	44	32	_	1	6	84	159	—	0	3	22	31
Nebraska† North Dakota	_	0 0	2 2	18	19 2	_	0 0	3 0	21	24	_	0 0	2 1	9	5 3
South Dakota	_	0	3	9	1	—	0	1	3	8	_	0	1	5	21
S. Atlantic Delaware	5	9 0	29 2	555 12	733 6	20	23 1	66 4	1,170 47	1,467 37	15	9 0	19 2	474 12	437 19
District of Columbia	4	0	1	8	6		0	2	9	13		0	5	33	14
Florida Georgia	4	4 1	13 6	217 65	289 124	16 2	8 4	15 8	427 179	510 202	10	3 0	9 3	171 29	119 39
Maryland† North Carolina	_	1 0	6 20	62 99	82 84	1	2 0	9 23	149 154	160 167	2	2 0	7 5	100 40	112 36
South Carolina [†]	_	0	3	24	45	_	2	5	83	163		0	1	5	16
Virginia† West Virginia	1	1 0	11 3	62 6	93 4	1	1 0	18 18	70 52	146 69	1	1 0	7 3	68 16	55 27
E.S. Central	1	2	8	127	235	3	7	20	392	370	1	2	9	107	90
Alabama [†] Kentucky	_	0 0	3 5	20 33	44 24	3	2 1	12 5	147 68	90 67	1	0 0	2 5	15 44	14 33
Mississippi Tennessee [†]	1	0 1	1 5	9 65	19 148	_	1 2	4 7	38 139	53 160	_	0 1	2 7	3 45	4 39
W.S. Central	_	6	77	335	552	_	17	, 315	798	946	_	1	32	61	78
Arkansas	_	0	9	38	20	—	1	3	50	73 70	—	0	3	3	9
Louisiana Oklahoma	_	0	3	25 9	65 6	_	0 0	17	37 73	61	_	0	6	7	10
Texas [†]	_	5	73	263	461	_	13	295	638	742	_	0	26	47	55
Mountain Arizona	4 3	5 3	17 16	270 168	348 195	1	3 0	16 4	141 9	204	2 1	2 1	8 4	120 39	100 26
Colorado Idaho†	1	1 0	3 2	39 9	49 21	_	0 0	5 2	34 15	63 16	_	0 0	2 3	22 11	20 4
Montana [†]	—	0	3	11	10	—	0	7	_	10	_	0	1	6	6
Nevada [†] New Mexico [†]	_	0 0	2 2	11 14	23 28	_	0 0	5 2	30 21	52 20	_	0 0	2 1	8 5	21 4
Utah Wyoming [†]	_	0 0	2 1	15 3	21 1	1	0 0	5 1	31 1	40 3	_1	0 0	6 0	29	15 4
Pacific	1	16	106	1,034	1,112	2	11	61	558	614	_	1	9	84	87
Alaska California	_	0 14	0	922	 971	—	0 8	3 41	9	8	—	0 1	0 9	84	1
Hawaii	_	0	88 3	13	24	_	0	1	408 6	412 10	_	0	0	_	83 3
Oregon [†] Washington	1	1 1	5 13	49 50	50 63	1 1	1 1	5 18	81 54	102 82	N	0 0	0 0	N	N
American Samoa	U	0	0	U	1	U	0	0	U	_	U	0	0	U	U
C.N.M.I. Guam	U	0 0	0 0	U	U 2	U	0 0	0 0	U	U 18	U	0 0	0 0	U	U
Puerto Rico	1	0	6	33	68	_	0	8	32	63	_	0	1	2	1
U.S. Virgin Islands	_	0	0	—	_	_	0	0	_	—	_	0	0	_	_

C.N.M.I.: Commonwealth of Northern Mariana Islands. U: Unavailable. —: No reported cases. N: Not notifiable. Cum: Cumulative year-to-* Incidence data for reporting year 2006 is provisional. * Contains data reported through the National Electronic Disease Surveillance System (NEDSS). Cum: Cumulative year-to-date counts. Med: Median. Max: Maximum.

(52nd Week)*			Lyme dis	ease				Malaria	3		
		Pre	evious			 	Prev		-		
Poporting area	Current week	52 v Med	veeks Max	Cum 2006	Cum 2005	urrent week	52 w Med	eeks Max	Cum 2006	Cum 2005	
Reporting area United States	73					5	26				
New England	8	220 18	2,153 780	17,002 2,920	23,364 4,757	э 	20 0	125 11	1,257 48	1,501 86	
Connecticut	7	9	753	1,694	1,810	_	0	3	11	24	
Maine [†] Massachusetts	_	1 0	34 3	287 33	247 2,336	_	0 0	1 3	4 19	5 39	
New Hampshire	—	3	95	567	271	_	0	3	10	6	
Rhode Island [†] Vermont [†]	1	0 1	93 15	235 104	39 54	_	0 0	8 1	3 1	10 2	
Mid. Atlantic	48	132	1,176	9,534	13,215	_	5	13	276	367	
New Jersey New York (Upstate)	 25	24 59	173 1,150	1,918 4,049	3,363 5,165	_	0 1	3 11	28 48	79 61	
New York City	25	0	1,150	4,049	400	_	3	9	153	190	
Pennsylvania	23	36	231	3,399	4,287	_	1	4	47	37	
E.N. Central Illinois	_	10 0	151 0	1,489	1,739 127	1	2 1	7 5	141 62	154 74	
Indiana	—	0	3	21	33	_	0	3	11	10	
Michigan Ohio	_	1 1	5 5	58 42	62 58	1	0 0	2 3	21 29	24 30	
Wisconsin	—	10	147	1,368	1,459	_	0	2	18	16	
W.N. Central lowa	_	5 1	169 8	846 87	1,035 91	_	0 0	32 1	62 2	79 9	
Kansas	_	0	8 2	5	3	_	0	2	2 8	9 7	
Minnesota Missouri	_	2 0	167 2	729 13	917 15	_	0 0	30 1	39 6	41 18	
Nebraska†	_	0	2	13	4	_	0	1	5	3	
North Dakota South Dakota	_	0 0	3 1	1	3 2	_	0 0	1 1	1 1	1	
S. Atlantic	16	29	117	1,939	2,349	3	6	14	323	329	
Delaware	—	7	28	466	646	_	0	1	5	3	
District of Columbia Florida	1	0 1	7 5	59 60	10 47	3	0 1	2 4	5 63	11 68	
Georgia		0	1	8	6	_	2	6	83	50	
Maryland [†] North Carolina	13	12 0	74 4	967 30	1,235 49	_	1 0	5 4	70 31	99 40	
South Carolina† Virginia†	2	0 4	2 29	18 317	21 274	_	0 1	2 9	10 54	11 44	
West Virginia	_	4 0	44	14	61	_	0	1	2	3	
E.S. Central	_	0	3	36	36	_	0	3	25	31	
Alabama [†] Kentucky	_	0 0	3 2	16 7	3 5	_	0 0	2 1	11 4	6 10	
Mississippi	—	0	1	1	—	—	0	1	4	_	
Tennessee [†] W.S. Central	1	0 0	2 3	12 20	28 77	_	0 1	2 31	6 84	15 153	
Arkansas	_	0	0	20	5	_	0	2	3	6	
Louisiana Oklahoma	_	0 0	0 0	_	3	_	0 0	1 2	5 7	5 12	
Texas [†]	1	Ő	3	20	69	_	1	29	69	130	
Mountain	_	0	3	28	23	1	1	9	68	63	
Arizona Colorado	_	0 0	2 1	7 1	10	1	0 0	9 2	23 17	22 25	
Idaho† Montana†	—	0	2 0	7	2	—	0	1	1 2	_	
Nevada [†]	_	0	1	3	3	_	0	1	2 4	4	
New Mexico† Utah	_	0 0	1	3 6	3 2	_	0 0	1 2	4 17	3 7	
Wyoming [†]	_	0	1	1	3	_	0	0		2	
Pacific	—	3	11	190	133	_	4	13	230	239	
Alaska California	_	0 3	1 9	3 169	4 95	_	0 3	4 8	23 154	7 177	
Hawaii	Ν	0	0	N	N	_	0	2	8	18	
Oregon [†] Washington	_	0 0	2 3	15 3	21 13	_	0 0	2 5	12 33	13 24	
American Samoa	U	0	0	U	U	U	0	0	U	U	
C.N.M.I. Guam	U	0 0	0 0	U	U	U	0 0	0	U	U	
Puerto Rico	Ν	0	0	N	Ν	_	0	1	1	4	
U.S. Virgin Islands	—	0	0	—	—	_	0	0	_	—	

C.N.M.I.: Commonwealth of Northern Mariana Islands. U: Unavailable. —: No reported cases. N: Not notifiable. Cum: Cumulative year-to-* Incidence data for reporting year 2006 is provisional. Contains data reported through the National Electronic Disease Surveillance System (NEDSS). Cum: Cumulative year-to-date counts. Med: Median. Max: Maximum.

(SZIIG WEEK)					jococcal d	isease, inva	sive								
			All serogi	oups					Inknown				Pertus	sis	
	Current		vious veeks	Cum	Cum	Current	Previ 52 we		Cum	Cum	Current		/ious /eeks	Cum	Cum
Reporting area	week	Med	Max	2006	2005	week	Med	Max	2006	2005	week	Med	Max	2006	2005
United States	2	20	85	1,063	1,264	_	13	58	688	783	149	255	2,877	13,144	25,616
New England	—	1 0	3 2	44 10	70 15	_	0 0	2 2	28 3	24 1	3	23 1	83 9	1,174 91	1,636
Connecticut Maine [†]	_	0	2	8	2	_	0	1	4	2	_	1	12	112	85 55
Massachusetts New Hampshire	_	0	2 2	15 6	32 12	_	0	2 2	15 6	7 12	3	13 2	30 36	594 190	1,167 186
Rhode Island [†]	—	Ō	1	2	4	_	Ō	0	_	_		0	17	70	53
Vermont [†] Mid. Atlantic	_	0 3	1 13	3 163	5 166		0 2	0 11		2 127	— 51	2 36	14	117	90
New Jersey	_	0	2	16	32	_	0	2	16	32	_	3	137 13	1,913 185	1,473 192
New York (Upstate) New York City	_	0 1	7 4	38 58	49 28	_	0 1	5 4	6 58	19 28	48	16 1	123 8	992 64	656 111
Pennsylvania	_	Ö	4	51	57	_	Ö	4	47	48	3	13	26	672	514
E.N. Central Illinois	_	2 0	12 4	120 18	159 34	_	1 0	7 4	86 18	125 34	17	41 9	133 22	2,100 453	3,913 922
Indiana	_	0	5	23	19	_	0	1	8	8	_	4	75	231	396
Michigan Ohio	_	0 1	3 4	22 43	35 45	_	0 1	1 3	11 35	18 39	1 16	12 11	39 29	617 631	321 1,185
Wisconsin	—	0	2	14	26	_	0	2	14	26	—	3	10	168	1,089
W.N. Central Iowa	_	1 0	4 2	65 22	86 18	_	0 0	2 1	22 6	36 1	_2	23 5	552 15	1,202 274	4,521 1,106
Kansas	_	0	1	3	11	_	0	1	3	11	—	5	19	320	542
Minnesota Missouri	_	0 0	3 2	16 14	17 28	_	0 0	2 1	6 2	6 13	1	0 5	485 14	164 301	1,571 656
Nebraska† North Dakota	_	0 0	2 1	6 1	6 2	_	0 0	1	4	3 2	1	2 0	9 25	97 26	295 168
South Dakota	—	Ő	1	3	4	_	Ő	Ó	_	_	—	Ő	4	20	183
S. Atlantic Delaware	—	4 0	14 1	205 6	222 4	—	2 0	7 1	87 6	104 4	36	18 0	46 1	1,051 3	1,450 16
District of Columbia	—	0	1	2	5	—	0	1	2	4	_	0	2	6	11
Florida Georgia	_	2 0	7 3	80 16	84 18	_	0 0	5 3	28 16	37 18	20	4 0	9 3	230 25	208 48
Maryland† North Carolina	_	0 0	2 11	15 32	22 32	_	0 0	1 3	5 12	5 9	 15	2 0	9 33	128 237	219 127
South Carolina [†]	_	0	2	24	14	—	0	2	10	9	1	3	11	173	405
Virginia† West Virginia	_	0 0	4 2	21 9	35 8	_	0 0	1 0	8	16 2	_	2 0	27 9	202 47	363 53
E.S. Central	1	1	4	51	61		1	4	40	48	6	6	28	424	516
Alabama [†] Kentucky	_	0	2 2	11 11	6 20	_	0	2 2	8 11	3 20	6	2 0	19 5	165 55	82 155
Mississippi		0	1	5	7	_	0	1	5	7	_	0	4	42	62
Tennessee [†] W.S. Central	1	0 1	23	24 58	28 129	_	0 0	2 6	16 25	18 35	 10	3 18	11 360	162 852	217 2,723
Arkansas	—	0	3	10	18	—	0	2	7	5	_	1	21	75	321
Louisiana Oklahoma	_	0 0	2 4	7 11	32 18	_	0 0	1 0	4	9 2	_	0 0	1 124	13 28	51 127
Texas [†]	—	0	16	30	61	_	0	4	14	19	10	15	215	736	2,224
Mountain Arizona	_	1 0	5 3	66 17	90 34	_	0 0	4 2	25 10	25 11	24 3	47 7	230 177	2,522 476	4,214 1,108
Colorado Idaho [†]	—	0	2	20 4	18 7	_	0	1 1	2 3	6	2	11	40	718	1,383
Montana [†]	_	0	1	4 5	_	_	0	1	3	_	1	1 2	8 9	86 109	220 586
Nevada† New Mexico†	_	0	1	4 6	14 5	_	0 0	0 1	3	2 4	_	0 2	9 8	66 128	50 196
Utah	_	0	1	6	12	_	0	1	1	2	18	13	39	861	618
Wyoming [†] Pacific	1	0 5	2 27	4 291	 281	—	0 5	2 25	4 248	 259	_	1 28	8 1,334	78 1,906	53 5,170
Alaska	_	0	1	3	4	_	0	1	3	4	—	1	7	65	159
California Hawaii	_	3 0	14 2	176 10	157 12	_	3 0	14 2	176 10	157 7	_	20 1	1,136 6	1,335 80	3,182 163
Oregon [†] Washington	1	1 0	7 9	64 38	55 53	—	1 0	4 7	45 14	55 36	—	2 5	8 195	105 321	619 1,047
American Samoa	U	0	9			 U	0	0	14 U	30 U	 U	0	195	52 I U	1,047 U
C.N.M.I.	Ŭ	0	0 0	_	1	U	0	0	Ŭ	Ū	Ŭ	0 0	0 0	Ŭ	Ŭ
Guam Puerto Rico	_	0	1	4	7	_	0	1	4	1 7	_	0	1	2	2 6
U.S. Virgin Islands	—	0	0	_	_	—	0	0	_	—	—	0	0	_	—

C.N.M.I.: Commonwealth of Northern Mariana Islands. U: Unavailable. —: No reported cases. N: Not notifiable. Cum: Cumulative year-to-* Incidence data for reporting year 2006 is provisional. * Contains data reported through the National Electronic Disease Surveillance System (NEDSS). Cum: Cumulative year-to-date counts. Med: Median. Max: Maximum.

(52nd Week)*															
		Ra Prev	abies, ani	mal		Roc	ky Mour Prev		tted feve	r			almonello vious	osis	
	Current		eeks	Cum	Cum	Current	52 w		Cum	Cum	Current	52 \	veeks	Cum	Cum
Reporting area United States	week 15	Med 123	Max 239	2006 6,110	2005 5,779	week 10	Med 35	Max 246	2006 2,092	2005 2,029	week 350	Med 754	Max 2,291	2006 41,924	2005 45,425
New England Connecticut Maine [†] Massachusetts	5 2 — 3	123 12 3 2 3 1	239 26 14 8 17 5	659 206 123 178	700 210 61 329	N	0 0 0 0 0	240 2 0 0 1	2,092 3 	2,029 10 N 6 1	4 — — 4	734 21 0 2 15 3	487 479 10 53 25	1,774 479 120 782 217	2,158 468 164 1,144
New Hampshire Rhode Island [†] Vermont [†]	- -	0	3 5	55 24 73	13 29 58		0	2 0	1	3	4 	5 1 1	25 17 6	95 81	177 112 93
Mid. Atlantic New Jersey New York (Upstate) New York City Pennsylvania	N 	27 0 10 1 16	71 0 24 5 56	1,586 N 542 44 1,000	999 N 565 28 406	2 2	1 0 0 1	6 1 2 3 3	86 7 5 24 50	100 30 2 7 61	33 — 23 1 9	83 14 25 23 28	272 48 233 50 67	4,997 803 1,311 1,219 1,664	5,273 960 1,427 1,196 1,690
E.N. Central Illinois Indiana Michigan Ohio Wisconsin	 N	2 0 1 0 0	18 7 2 5 9 0	162 46 11 47 58 N	173 51 12 40 70 N	 	1 0 0 0 0	6 2 1 1 4 1	44 5 7 5 26 1	41 11 6 21 2	13 3 10	100 23 15 18 23 17	192 56 67 35 56 27	5,061 1,163 828 972 1,291 807	5,743 1,837 680 952 1,338 936
W.N. Central Iowa Kansas Minnesota Missouri Nebraska† North Dakota South Dakota		6 1 0 1 0 0 0	20 7 5 6 0 7 4	306 57 82 40 67 24 36	328 — 80 71 73 — 36 68		2 0 0 2 0 0 0	14 1 2 12 5 1 0	206 5 1 5 170 25 —	155 7 5 128 7 1 5	8 — — 8 —	48 8 7 11 14 3 0 3	109 26 16 60 35 9 46 7	2,625 442 367 704 754 197 28 133	2,618 410 369 573 801 219 86 160
S. Atlantic Delaware District of Columbia Florida Georgia Maryland [†] North Carolina South Carolina [†] Virginia [†] West Virginia	8 - - - - - - -	41 0 0 5 6 9 3 11 2	183 0 167 10 13 22 11 27 7	2,155 — 176 253 318 512 177 601 118	2,087 201 256 380 459 225 495 71	6 5 1 	20 0 1 1 17 0 2 0	72 3 1 3 5 6 5 5 13 2	1,174 21 1 28 50 80 842 36 113 3	1,013 7 2 14 86 75 625 73 121 10	188 — 160 8 6 — 12 2 —	206 2 1 92 30 13 33 18 20 1	398 10 4 176 77 30 130 51 57 19	11,504 144 62 4,929 1,777 728 1,691 1,011 1,022 140	13,018 126 60 5,552 1,929 806 1,713 1,445 1,172 215
E.S. Central Alabama [†] Kentucky Mississippi Tennessee [†]	1 1 —	4 1 0 2	16 8 4 2 9	254 84 28 4 138	149 79 17 5 48	2 2 —	6 2 0 0 4	31 11 1 22	400 136 3 4 257	289 72 3 18 196	42 31 3 	60 24 8 12 15	153 92 23 42 32	3,385 1,387 448 757 793	2,966 739 488 904 835
W.S. Central Arkansas Louisiana Oklahoma Texas [†]	 	11 0 1 10	34 5 0 9 29	569 32 66 471	856 36 79 741	 	1 0 0 0	161 10 1 154 4	119 51 5 38 25	379 137 6 206 30	4 4 	67 15 13 9 31	922 47 42 48 839	4,194 924 825 501 1,944	5,240 739 908 448 3,145
Mountain Arizona Colorado Idaho [†] Montana [†] Nevada [†] New Mexico [†] Utah Wyoming [†] Pacific Alaska California		3 2 0 0 0 0 0 0 0 3 0 3	27 10 0 25 2 1 2 1 2 1 2 12 4 11	207 137 	270 169 18 12 15 14 10 15 17 217 4 205		0 0 0 0 0 0 0 0 0 0 0	6 6 1 3 2 1 2 2 1 1 0 1	53 10 2 14 2 3 9 6 7 7 5	40 25 4 3 1 4 	39 11 12 1 — 13 2 19 1	50 18 12 3 2 3 4 5 1 113 113 86	88 67 30 9 10 20 15 15 4 426 7 292	2,568 900 606 175 129 186 242 284 46 5,816 76 4,550	2,473 746 582 150 149 200 251 310 85 5,936 60 4,546
Hawaii Oregon [†] Washington American Samoa	 U U	0 0 0	0 4 0	25 U U	8 U U	 N U	0 0 0	0 1 0 0	2 N U	2 N U	— 18 U	5 8 10 0	16 16 124 0	262 418 510 U	290 410 630 7
C.N.M.I. Guam Puerto Rico U.S. Virgin Islands	U 	0 0 1 0	0 0 6 0	Ŭ 68 	Ŭ 71	U N 	0 0 0 0	0 0 0 0	U N	U 	U 2 —	0 1 4 0	0 1 35 0	Ŭ 260	U 46 690

C.N.M.I.: Commonwealth of Northern Mariana Islands. U: Unavailable. —: No reported cases. N: No U: Unavailable. —: No reported cases. N: Not notifiable. Cum: Cumulative year-to- * Incidence data for reporting year 2006 is provisional. * Contains data reported through the National Electronic Disease Surveillance System (NEDSS). Cum: Cumulative year-to-date counts. Med: Median. Max: Maximum.

(52nd Week)*	Shig	a toxin-p	roducing	E. coli (S1	TEC)†		Sh	igellosi	s		Strepto	coccal d	isease, i	nvasive, g	roup A
		Prev	vious				Prev		-		<u>.</u>	Prev	ious		<u> </u>
Reporting area	Current week	52 w Med	eeks Max	Cum 2006	Cum 2005	Current week	52 w Med	eeks Max	Cum 2006	Cum 2005	Current week	52 w Med	eeks Max	Cum 2006	Cum 2005
United States	19	56	297	3,199	3,502	101	251	1,013	13,660	16,190	61	85	282	4,678	4,733
New England	1	2	73	251	228	_	3	70	231	324		3	15	183	285
Connecticut Maine [§]	1	0 0	72 8	72 45	63 29	_	0 0	64 2	64 6	58 15	U	0 0	1 2	U 16	100 14
Massachusetts New Hampshire	_	1 0	9 3	82 27	87 19	_	2 0	11 2	128 12	192 19	_	2 0	6 9	101 44	130 18
Rhode Island [§] Vermont [§]	_	0 0	2	8	9 21	_	0	3	15 6	23 17	_	0	3	8 14	12 11
Mid. Atlantic	2	5	107	416	463	3	15	72	813	1,296	13	18	43	891	903
New Jersey New York (Upstate)	_	0 0	2 103	3 10	78 237	2	3 4	34 60	242 230	318 329	 10	2 5	8 32	122 310	179 276
New York City	_	0	4	37	17	_	4	13	253	416	_	2	8	142	171
Pennsylvania E.N. Central	2	2 10	49 56	202 640	131 643	1 4	1 20	6 38	88 1,029	233 1,205	3 3	6 13	13 44	317 766	277 913
Illinois	_	1	7	83	140	-	7	21	376	409	_	2	11	144	307
Indiana Michigan	_	1 1	8 6	86 93	77 95	_	2 3	18 8	165 148	191 241	1	2 3	11 12	112 215	110 212
Ohio Wisconsin	_	3 2	18 39	196 182	170 161	4	3 3	14 9	197 143	139 225	_2	4 1	19 4	239 56	192 92
W.N. Central	3	11	35	650	553	4	36	77	1,767	1,785	1	5	57	349	306
lowa Kansas	_	2 0	22 4	139 29	100 54	_	2 2	10 11	121 139	103 272	N	0 1	0 5	N 54	N 40
Minnesota Missouri	_	4 0	27 1	247	181 98	4	3 9	24 69	243 654	96 1,017	1	0 1	52 5	156 85	122 73
Nebraska§	_	0	8	55	64	_	1	14	127	160	_	1	4	33	27
North Dakota South Dakota	_	0 0	15 5	49	23 33	_	0 6	18 24	103 380	6 131	_	0 0	5 2	11 10	18 26
S. Atlantic	10	8 0	39 3	486 12	463 9	65	59 0	150 2	3,438 11	2,514 11	24	23 0	45 2	1,166 10	960 6
Delaware District of Columbia	_	0	1	3	2	_	0	2	17	15	_	Ō	2	18	13
Florida Georgia	9	2 2	29 7	106 84	132 49	59 3	27 21	76 63	1,646 1,286	1,270 672	13 7	5 5	16 12	313 249	260 203
Maryland [§] North Carolina	1	2 2	8 11	102 122	75 64	3	2 1	10 21	128 160	103 202	4	4 0	12 26	201 157	178 124
South Carolina§	—	0	2	10	14	—	1	9	73	105	—	1	6	63	39
Virginia [§] West Virginia	_	0 0	8 5	12	111 7	_	2 0	9 2	111 6	134 2	_	2 0	11 6	128 27	110 27
E.S. Central Alabama [§]	1	2 0	12 5	101 49	177 30	4	15 5	83 74	1,008 490	1,200 225	N	3 0	11 0	193 N	180 N
Kentucky	_	1	12	101	76	1	4	15	234	335	_	Ō	5	38	35
Mississippi Tennessee [§]	_	0 0	0 4	24	8 63	1	2 2	9 12	111 173	102 538	_	0 3	0 9	155	145
W.S. Central	1	1	52	83	169	_	35	596	1,836	4,236	3	7	58	361	397
Arkansas Louisiana	1	0 0	7 0	40	13 22	_	2 1	9 25	125 143	62 137	_	0 0	5 2	27 9	23
Oklahoma Texas§	3	0 2	17 44	43 130	38 96	_	2 29	286 308	135 1,433	937 3,100	3	2 4	14 43	100 225	132 242
Mountain	_	5	17	316	316	18	25	87	1,499	993	15	11	77	637	661
Arizona Colorado	_	2 1	13 8	129 102	35 83	13 2	12 3	35 15	742 235	547 170	5 7	5 2	57 8	335 141	303 184
Idaho [§] Montana [§]	_	1 0	7 0	83	53 16	_	0 0	3 13	15 64	19 5	_	0 0	2 0	11	5
Nevada§	_	0 0	5 1	25	28 25	_	1	20	107	64	1	0	0 7	 74	 95
New Mexico [§] Utah	1	1	14	4 123	66	_	2 1	15 6	168 82	137 46	2	1	7	72	69
Wyoming [§]	_	0	3	20	10	3	0	19	86	5	_	0	1	4	5
Pacific Alaska	2	4 0	50 0	256	490	3	37 0	148 2	2,039 9	2,637 13	2	2 0	9 0	132	128
California Hawaii	_	0 0	18 2	 18	182 13	_	29 1	104 4	1,716 44	2,278 35	2	0 2	0 9	132	128
Oregon [§] Washington	2	0	1 32	1 127	158 137	3	1 2	32 43	120 150	126 185	N	0	0	N	N
American Samoa	2 U	2	32 0	127 U	137 U	J U	2	43 0	150 U	7	U	0	0	U	U
C.N.M.I. Guam	Ŭ	0	0	Ū	Ŭ	Ŭ	0	0	Ŭ	Ú 20	Ŭ	0	0	Ŭ	Ŭ
Puerto Rico	_	0	0	_	2	_	0	2	13	9	N	0	0	Ν	Ν
U.S. Virgin Islands	-	0	0	_	—	—	0	0	_	_	_	0	0	_	

C.N.M.I.: Commonwealth of Northern Mariana Islands. U: Unavailable. —: No reported cases. N: No N: Not notifiable.

Cum: Cumulative year-to-date counts.

Max: Maximum.

Med: Median.

¹ Incidence data for reporting year 2006 is provisional.
 ¹ Incidence data for reporting year 2006 is provisional.
 ¹ Incidence *E. coli* O157:H7; Shiga toxin positive, serogroup non-0157; and Shiga toxin positive, not serogrouped.
 ⁸ Contains data reported through the National Electronic Disease Surveillance System (NEDSS).

2nd Week)*	Strepto		<i>neumonia</i> resistant,	<i>e</i> , invasive all ages	disease	Sypl	nilis, prin	nary and	seconda	ry		Varice	ella (chic	kenpox)	
			/ious				Previ						/ious	_	
porting area	Current week	52 w Med	veeks Max	Cum 2006	Cum 2005	Current week	52 we Med	eks Max	Cum 2006	Cum 2005	Current week	52 w Med	veeks Max	Cum 2006	Cum 2005
ited States	49	50	333	2,557	2,880	45	175	334	8,852	8,724	213	849	2,857	42,173	32,465
w England	2	0	24	42	255	6	4	17	189	225	12	29	59	1,470	5,286
nnecticut aine†	U	0	7 2	U 9	106 N	_	0 0	11 2	29 8	58 1	U	0 0	20 16	U 151	1,709 331
assachusetts w Hampshire	_	0 0	5 0	_	107	5	2 0	6 2	123 13	125 16	3	0 6	17 47	94 483	2,214 337
iode Island†	_	0	11	15	29	_	0	2	13	24	_	0	0	_	—
rmont [†]	2	0	2	18	13	1	0	1	3	1	9	12	50	742	695
d. Atlantic w Jersey	3 N	3 0	15 0	182 N	216 N	6	21 3	35 8	1,108 150	1,037 133	29	105 0	184 0	5,061	4,966
w York (Upstate) w York City	2 U	1 0	10 0	70 U	88 U	4	3 10	14 23	149 543	89 616	_	0 0	0 0	_	_
nnsylvania	1	2	9	112	128	2	5	12	266	199	29	105	184	5,061	4,966
N. Central nois	8	11 0	44 2	586 18	645 39	14 5	15 7	38 23	829 368	944 525	45	327 1	587 7	15,148 68	6,239 106
liana	_	3	21	159	199	—	1	5	88	62	—	0	475	475	_
chigan nio	8	0 6	3 42	18 391	50 357	5 3	2 3	19 8	119 185	105 211	16 29	111 153	250 420	5,070 8,761	3,916 1,725
sconsin	N	Ō	0	N	N	1	1	4	69	41	_	14	52	774	492
N. Central va	N	1 0	191 0	107 N	236 N	_	5 0	13 3	263 19	252 9	12 N	30 0	98 0	1,917 N	695 N
nsas	N	0	0	N 60	Ν	—	0	3	26	19 70	—	5	27 0	358	_
nnesota ssouri	_	1	191 3	60 42	191 37	_	3	2 8	32 165	70 147	12	0 24	82	1,399	477
ebraska† orth Dakota	_	0 0	1 0	1	2 3	_	0 0	2 1	7 1	4 1	_	0 0	0 17	 45	82
outh Dakota	—	Ő	3	4	3	—	Ő	3	13	2	—	1	15	115	136
Atlantic laware	36	26 0	53 0	1,363	1,155 3	13	41 0	186 3	2,111 20	2,311 11	10	88 1	860 6	4,379 66	3,735 35
strict of Columbia	_	0	3	27	17	_	2	8	121	114	_	0	5	48	43
orida eorgia	31 5	14 7	31 28	771 460	614 389	10	14 7	23 147	727 404	724 645	_	0 0	0 0	_	_
aryland† orth Carolina	N	0 0	0 0	N	N	3	5 5	14 17	288 292	313 274	_	0 0	0 0	_	_
uth Carolina [†]	—	0	0	_	—	—	1	5	66	84	10	19	53	1,123	680
ginia† est Virginia	N	0 1	0 14	N 105	N 132	_	3 0	17 1	187 6	143 3	_	28 27	812 70	1,673 1,469	1,834 1,143
S. Central		2	13	142	199	5	14	27	732	487	14	3	39	240	306
abama† ntucky	N	0 0	0 0	<u>N</u>	N 32	_	6 1	19 9	320 74	169 52	14 N	2 0	39 0	238 N	306 N
ssissippi nnessee⁺	_	0 2	0 13	142	1 166	3 2	1 5	8 13	87 251	49 217	N	0 0	1 0	2 N	N
S. Central	_	0	5	28	121	_	29	54	1,523	1,247	65	191	1,757	11,073	8,624
kansas uisiana	_	0 0	3 4	12 16	14 107	_	1 4	6 27	78 297	52 278	_	14 1	110 8	926 68	159 129
lahoma	N	0	0	N	Ν	_	1	6	74	44	_	0	0	_	—
	N					_			,					,	8,336 2,614
zona	N	0	0	N	Ν	_	3	16	187	175	_	0	0	· —	· —
olorado aho†	N N	0 0	0 0	N N	N N	_	1 0	3 1	43 2	46 20	20	30 0	76 0	1,455	1,797
ontana [†]	—	0	0	_	1	—	0	1	1	7	—	0	13	33	_
w Mexico [†]	_	0	0	_	_	_	1	5	62	56	_	4	34	356	213
ah /oming†	_	1	10 4	63 44	26 26	_	0 0	2 0	10	10	6	18 1	65 11	977 64	551 53
cific	_	0	0	_	_	1	35	52	1,683	1,798	_	0	0	_	_
aska Ilifornia	N	0 0	0 0	N	N	_			9 1,450		_	0 0	0 0	_	_
waii		0	0	N		_	0	2	17	11	N	0	0	N	N N
ashington	N	0	0	N	N	1	2	10	182	152	N	0	0	N	N
nerican Samoa	—	0	0	—	—	U	0	0	U	U	U	0	0	U	U U
iam	_	0	0	_	_	_	0	0	_	3		2	4	_	445
erto Rico S. Virgin Islands	N	0 0	0 0	N		_	3 0	10 0	141	222	_	6 0	47 0	330	762
xas [†] puntain izona ilorado hot [†] pontana [†] ivada [†] ivw Mexico [†] ah yoming [†] cific aska lifornia iwwaii egon [†] ashington herican Samoa N.M.I. iam ierto Rico	N Z Z Z Z Z	0 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	0 10 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	N 107 N N N 63 44 N N N N N	N 53 N N 1 26 26 N N N N N N N N N N N N N N N N N N	 	22 8 3 1 0 0 2 1 0 0 35 0 29 0 0 2 0 0 0 3 3	34 25 16 3 1 12 5 2 0 52 4 43 2 6 10 0 0 0 0 10	1,074 414 187 43 2 1 1 09 62 10 - - - 1,683 9 1,450 17 25 182 U U U - 141	873 423 175 46 20 7 109 56 10 — 1,798 9 1,585 11 41 152 U U 3 222	 6 N N N	170 61 0 0 0 4 18 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	1,647 137 0 76 0 13 0 34 65 11 0 0 0 0 0 0 0 0 0 0 0 0 4 47	356 977 64 N N N U U U	2,

C.N.M.I.: Commonwealth of Northern Mariana Islands. U: Unavailable. —: No reported cases. N: Not notifiable. Cum: Cumulative year-to-* Incidence data for reporting year 2006 is provisional. Contains data reported through the National Electronic Disease Surveillance System (NEDSS). Cum: Cumulative year-to-date counts. Med: Median. Max: Maximum.

(52nd Week)*					West Nile	virus diseas	set					
			Neuroinva	sive				No	n-neuroin	vasive		
	0		vious	0	0		0		ious	0	0	
Reporting area	Current week	Med	reeks Max	Cum 2006	Cum 2005		Current week	<u>52 w</u> Med	<u>еекs</u> Мах	Cum 2006	Cum 2005	
United States	_	1	177	1,371	1,192		_	1	399	2,732	1,683	
New England	_	0	3	9	9		—	0	2	3	4	
Connecticut Maine [§]	_	0 0	3 0	7	4		_	0 0	1 0	2	2	
Massachusetts	_	0	1	2	4		_	0	1	1	2	
New Hampshire Rhode Island [§]	_	0 0	0 0	_	1		_	0 0	0 0	_	_	
Vermont [§]	_	0	0	_	_		_	0	0	_	_	
Mid. Atlantic	_	0	11	26	47		_	0	4	11	22	
New Jersey	—	0	2	2	3		_	0	1	3	3	
New York (Upstate) New York City	_	0 0	5 4	8 8	19 11		_	0 0	1 2	3 4	5 3	
Pennsylvania	_	0	2	8	14		_	0	1	1	11	
E.N. Central	_	0	43	243	259		_	0	33	167	156	
Illinois Indiana	_	0 0	23 7	121 28	137 11		_	0 0	23 12	89 53	115 12	
Michigan	_	0	11	47	54		_	0	2	5	8	
Ohio	_	0	11	36	46		_	0	3	11	15	
Wisconsin	—	0	2	11	11		_	0	2	9	6	
W.N. Central lowa	_	0 0	36 3	222 21	169 14		_	0 0	79 4	484 15	463 23	
Kansas	—	0	3	17	17		—	0	3	13	N	
Minnesota Missouri	_	0 0	6 14	30 51	18 17		_	0 0	7 2	35 10	27 13	
Nebraska§	_	0	9	45	55		_	0	38	219	133	
North Dakota	—	0	5	20	12		—	0	28	117	74	
South Dakota	_	0	7	38	36		_	0	22	75	193	
S. Atlantic Delaware	_	0 0	2 0	16	34 1		_	0 0	7 0	13	29 1	
District of Columbia	—	0	0		3		—	0	1	1	2	
Florida Georgia	_	0 0	1	3 2	10 9		_	0 0	0 4	6	11 11	
Maryland [§]	_	0	2	8	4		_	0	2	2	1	
North Carolina	—	0	1	1	2		_	0	0	—	2	
South Carolina [§] Virginia [§]	_	0 0	1 0	1	5		_	0 0	0 2	4	1	
West Virginia	_	Ō	1	1	_		Ν	0	0	N	Ň	
E.S. Central	—	0	15	117	65		—	0	16	95	38	
Alabama [§] Kentucky	_	0 0	2 2	7 5	6 5		_	0 0	0 1	1	4	
Mississippi	_	0	10	89	39		_	0	16	92	31	
Tennessee [§]	_	0	4	16	15		—	0	2	2	3	
W.S. Central Arkansas	_	0 0	58 4	357 23	158 13		_	0 0	26 2	217 5	150 15	
Louisiana	_	0	13	89			_	0	9	83	54	
Oklahoma	—	0	6	28	17		—	0	4	19	14	
Texas [§]	_	0	38	217	128		_	0	16	110	67	
Mountain Arizona	_	0 0	57 0	295	145 52		_	1 0	228 15	1,484 97	240 61	
Colorado	_	0	10	64	21		—	0	51	269	85	
Idaho [§] Montana [§]	_	0 0	30 3	111 12	3 8		_	0 0	157 8	850 22	10 17	
Nevada§	_	0	9	34	14		_	0	16	89	17	
New Mexico [§]	—	0	1	3	20		_	0	1	5	13	
Utah Wyoming [§]	_	0 0	8 7	56 15	21 6		_	0 0	17 10	102 50	31 6	
Pacific	_	0	15	86	306		_	0	51	258	581	
Alaska	—	0	0	_	_		—	0	0	_	_	
California Hawaii	_	0 0	15 0	79	305		_	0 0	37 0	193	575	
Oregon [§]	_	0	2	7	1		_	0	14	62	6	
Washington	—	0	0	—	—		—	0	2	3	—	
American Samoa	U	0 0	0	U	U		U	0	0	U U	U U	
C.N.M.I. Guam	U	0	0	<u> </u>	U		<u> </u>	0 0	0 0			
Puerto Rico	_	0	0	—	_		—	0	0	—	—	
U.S. Virgin Islands	_	0	0	_	_		_	0	0	_	_	

C.N.M.I.: Commonwealth of Northern Mariana Islands.

U: Unavailable. —: No reported cases. N: Not notifiable. Cum: Cumulative year-to-date counts.

* Incidence data for reporting year 2006 is provisional.

¹ Updated weekly from reports to the Division of Vector-Borne Infectious Diseases, National Center for Zoonotic, Vector-Borne, and Enteric Diseases (proposed) (ArboNET Surveillance). [§] Contains data reported through the National Electronic Disease Surveillance System (NEDSS).

Med: Median.

Max: Maximum.

TABLE III. Deaths in 122 U.S. cities.* week ending December 30, 2006 (52nd Week)


TABLE III. Deaths	<u>in 122 U.</u> 			ending I y age (ye		ber 30), 2006 (52nd Week)	All causes, by age (years)						
	AII						P&I [†]		All	,.,					P&I [†]
Reporting Area	Ages	<u>></u> 65	45-64	25-44	1-24	<1	Total	Reporting Area	Ages	<u>></u> 65	45-64	25-44	1-24	<1	Total
New England	554	395	114	32	3	10	45	S. Atlantic	961	609	226	86	20	20	58
Boston, MA Bridgeport, CT	136 36	95 25	28 10	8	2	3 1	9 7	Atlanta, GA Baltimore, MD	45 143	26 80	16 38	3 18	2	5	2 17
Cambridge, MA	25	20	3	2	_	_	1	Charlotte, NC	88	59	21	5	1	2	7
Fall River, MA	28	23	3	2	_	_	_	Jacksonville, FL	106	67	27	9	2	1	. 9
Hartford, CT	41	31	7	3	_	—	7	Miami, FL	110	80	16	10	2	2	2
Lowell, MA	30	22	7	1	—	_	2	Norfolk, VA	39	29	5	3	2	2	1
Lynn, MA New Bedford, MA	11 29	5 23	4 5	2	_	1	2 4	Richmond, VA Savannah, GA	65 44	39 27	17 12	5 4	2	2	2 2
New Haven, CT	29	19	7	2	_	_	3	St. Petersburg, FL	61	40	15	4	1	1	5
Providence, RI	53	34	8	6	1	4	5	Tampa, FL	139	88	27	18	4	2	6
Somerville, MA	3	3	—	—	—	_	—	Washington, D.C.	99	58	27	7	3	4	2
Springfield, MA	41	28	11	2	_	_	2	Wilmington, DE	22	16	5	_	1	—	3
Waterbury, CT	36	26	10	4	_	1	3	E.S. Central	603	409	138	34	10	12	53
Worcester, MA	57	41	11		_		_	Birmingham, AL	93	62	19	7	_	5	13
Mid. Atlantic	2,017	1,427	415	112	38	25	99	Chattanooga, TN	40	28	6	2	3	1	3
Albany, NY	50	39	8	2	1	1	1	Knoxville, TN	71 11	57 8	9 2	5	1	_	7 1
Allentown, PA Buffalo, NY	25 94	18 64	3 21	1 7	2	_2	8	Lexington, KY Memphis, TN	176	112	2 49	10	2	3	15
Camden, NJ	36	21	10	2	3	_	2	Mobile, AL	68	48	14	3	3	_	3
Elizabeth, NJ	18	12	4	2	_	_	2	Montgomery, AL	33	22	9	1	_	1	3
Erie, PA	50	37	12	_	1	—	5	Nashville, TN	111	72	30	6	1	2	8
Jersey City, NJ	30	22	4	3		1	1	W.S. Central	1,007	646	254	56	23	28	52
New York City, NY	979 27	701 14	196 7	59 4	12 2	11	41 1	Austin, TX	70	47	16	4	1	2	5
Newark, NJ Paterson, NJ	27 U	14 U	Ű	4 U	2 U		Ŭ	Baton Rouge, LA	51	32	15	4	_	_	—
Philadelphia, PA	323	188	96	17	15	7	8	Corpus Christi, TX	35	23	12				3
Pittsburgh, PA§	22	17	4	1	_	_	_	Dallas, TX El Paso, TX	135 U	87 U	33 U	10 U	1 U	4 U	8 U
Reading, PA	32	25	7	—	—	_	3	Fort Worth, TX	91	61	20	7	1	2	4
Rochester, NY	137	101	26	6	2	2	12	Houston, TX	240	128	76	17	10	9	8
Schenectady, NY Scranton, PA	23 26	20 21	3 2	3	_	_	2 1	Little Rock, AR	54	30	16	3	2	3	_
Syracuse, NY	88	77	6	4	_	1	7	New Orleans, LA ¹	U	U	U	U	U	U	U
Trenton, NJ	24	20	4	_	_		3	San Antonio, TX	193	136	42	8	4	3	14
Utica, NY	13	12	1	_	_	—	1	Shreveport, LA Tulsa, OK	26 112	22 80	3 21	3	1 3	5	10
Yonkers, NY	20	18	1	1	_	_	1								
E.N. Central	1,562	1,047	358	104	25	28	107	Mountain Albuquerque, NM	978 121	646 84	199 22	79 12	32 1	22 2	66 7
Akron, OH	U	U	U	U	U	U	U	Boise, ID	50	35	6	5	1	3	_
Canton, OH	45	31	12 70	 19	7	2 5	4	Colorado Springs, CO		23	3	2	2	_	2
Chicago, IL Cincinnati, OH	283 46	182 25	11	5	2	э 3	18 4	Denver, CO	U	U	U	U	U	U	U
Cleveland, OH	212	152	46	12	2	_	12	Las Vegas, NV	309	206	64	23	10	6	27
Columbus, OH	179	117	44	14	1	3	15	Ogden, UT Phoenix, AZ	39 161	29 91	7 42	2 18	1 6	4	3 10
Dayton, OH	98	62	23	10	2	1	6	Pueblo, CO	32	22	42	4	2	-	2
Detroit, MI	116	64	36	9	6	1	9	Salt Like City, UT	125	79	32	6	5	3	6
Evansville, IN Fort Wayne, IN	33 U	21 U	6 U	6 U			2 U	Tucson, AZ	111	77	19	7	4	4	9
Gary, IN	16	9	3	2	1	1	_	Pacific	931	673	185	43	21	8	68
Grand Rapids, MI	63	44	16	_	1	2	5	Berkeley, CA	U	U	U	U	U	Ŭ	U
Indianapolis, IN	138	90	37	5	2	4	8	Fresno, CA	U	U	U	U	U	U	U
Lansing, MI	U	U	U	U	U	U	U	Glendale, CA	U	U	U	U	U	U	U
Milwaukee, WI Peoria, IL	72 39	49 30	12 5	10 2	_	1 2	10	Honolulu, HI	70 65	49 45	15 13	2 7	2	2	3
Rockford, IL	39 70	30 55	5 9	2	1	2	1 3	Long Beach, CA Los Angeles, CA	65 U	45 U	U	Ú		 U	16 U
South Bend, IN	24	18	4	2		_	3	Pasadena, CA	18	10	4	3	1	_	1
Toledo, OH	82	60	16	5	_	1	5	Portland, OR	85	55	19	5	4	1	6
Youngstown, OH	46	38	8	—	—	_	2	Sacramento, CA	164	125	27	5	3	4	11
W.N. Central	501	316	138	27	9	9	31	San Diego, CA	107	83	16	4	4	_	7
Des Moines, IA	30	23	7	—	_	_	5	San Francisco, CA San Jose, CA	38 126	28 94	9 25	1 6	1	_	2 7
Duluth, MN	28	24	3	1	—	_	2	Santa Cruz, CA	28	94 20	25 8	6	_	_	4
Kansas City, KS	17	6	9	1		1	_	Seattle, WA	62	40	15	6	1	_	2
Kansas City, MO Lincoln, NE	88 41	48 31	23 9	8	8	1	3 2	Spokane, WA	41	33	6	1	_	1	4
Minneapolis, MN	41	26	9 16	6	_	1	2	Tacoma, WA	127	91	28	3	5	—	5
Omaha, NE	75	53	20	2	_	_	10	Total	9,114**	6,168	2,027	573	181	162	579
St. Louis, MO	86	42	32	6	1	3	5		,	,	,				
St. Paul, MN	44	30	11	1	_	2									
Wichita, KS	43	33	8	2	_	_	1								

U: Unavailable.

U: Unavailable. —:No reported cases. Mortality data in this table are voluntarily reported from 122 cities in the United States, most of which have populations of ≥100,000. A death is reported by the place of its occurrence and by the week that the death certificate was filed. Fetal deaths are not included. [†] Pneumonia and influenza.

¹Because of changes in reporting methods in this Pennsylvania city, these numbers are partial counts for the current week. Complete counts will be available in 4 to 6 weeks. ¹Because of Hurricane Katrina, weekly reporting of deaths has been temporarily disrupted. ** Total includes unknown ages.

FIGURE I. Selected notifiable disease reports, United States, comparison of provisional 4-week totals December 30, 2006, with historical data



* No measles or rubella cases were reported for the current 4-week period yielding a ratio for week 52 of zero (0).
[†] Ratio of current 4-week total to mean of 15 4-week totals (from previous, comparable, and subsequent 4-week periods for the past 5 years). The point where the hatched area begins is based on the mean and two standard deviations of these 4-week totals.

Notifiable Disease Data Team and 122 Cities Mortality Data TeamPatsy A. HallDeborah A. AdamsRosaline DharaWillie J. AndersonVernitta LoveLenee BlantonPearl C. Sharp

Recommended Immunization Schedules for Persons Aged 0–18 Years — United States, 2007

Weekly

January 5, 2007 / Vol. 55 / Nos. 51 & 52

The Advisory Committee on Immunization Practices (ACIP) periodically reviews the recommended immunization schedule for persons aged 0–18 years to ensure that the schedule is current with changes in vaccine formulations and reflects revised recommendations for the use of licensed vaccines, including those newly licensed.

QuickGuide

The changes to the previous childhood and adolescent immunization schedule, published January 2006 (1), are as follows:

- The new rotavirus vaccine (Rota) is recommended in a 3-dose schedule at ages 2, 4, and 6 months. The first dose should be administered at ages 6 weeks through 12 weeks with subsequent doses administered at 4–10 week intervals. Rotavirus vaccination should not be initiated for infants aged >12 weeks and should not be administered after age 32 weeks (2).
- The influenza vaccine is now recommended for all children aged 6–59 months (*3*).
- Varicella vaccine recommendations are updated. The first dose should be administered at age 12–15 months, and a newly recommended second dose should be administered at age 4–6 years (4).
- The new human papillomavirus vaccine (HPV) is recommended in a 3-dose schedule with the second and third doses administered 2 and 6 months after the first dose. Routine vaccination with HPV is recommended for females aged 11–12 years; the vaccination series can be started in females as young as age 9 years; and a catch-up vaccination is recommended for females aged 13–26 years who have not been vaccinated previously or who have not completed the full vaccine series (5).

Suggested citation: Centers for Disease Control and Prevention. Recommended immunization schedules for persons aged 0–18 years—United States, 2007. MMWR 2006;55(51&52):Q1–Q4.

• The main change to the format of the schedule is the division of the recommendation into two schedules: one schedule for persons aged 0–6 years (Figure 1) and another for persons aged 7–18 years (Figure 2). Special populations are represented with purple bars; the 11–12 years assessment is emphasized with the bold, capitalized fonts in the title of that column. Rota, HPV, and varicella vaccines are incorporated in the catch-up immunization schedule (Table).

Vaccine Information Statements

The National Childhood Vaccine Injury Act requires that health-care providers provide parents or patients with copies of Vaccine Information Statements before administering each dose of the vaccines listed in the schedule. Additional information is available from state health departments and from CDC at http://www.cdc.gov/nip/publications/vis.

Detailed recommendations for using vaccines are available from package inserts, ACIP statements on specific vaccines, and the 2003 Red Book (6). ACIP statements for each recommended childhood vaccine are available from CDC at http://www.cdc.gov/nip/publications/acip-list.htm. In addition, guidance for obtaining and completing a Vaccine Adverse Event Reporting System form is available at http:// www.vaers.hhs.gov or by telephone, 800-822-7967.

References

- 1. CDC. Recommended childhood and adolescent immunization schedule—United States. MMWR 2006;54(52):Q1–Q4.
- CDC. Prevention of rotavirus gastroenteritis among infants and children. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2006;55(No. RR-12):1–13.
- 3. CDC. Prevention and control of influenza. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2006;55(No. RR-10):1-42.
- CDC. ACIP provisional recommendations for the prevention of varicella. Available at http://www.cdc.gov/nip/vaccine/varicella/varicella_ acip_recs_prov_june_2006.pdf.
- CDC. ACIP provisional recommendations for the use of quadrivalent HPV vaccine. Available at http://www.cdc.gov/nip/recs/provisional_ recs/hpv.pdf.
- American Academy of Pediatrics. Active and passive immunization. In: Pickering LK, ed. 2003 red book: report of the Committee on Infectious Diseases. 26th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2003.

The recommended immunization schedules for persons aged 0–18 years and the catchup immunization schedule for 2007 have been approved by the Advisory Committee on Immunization Practices, the American Academy of Pediatrics, and the American Academy of Family Physicians. The standard *MMWR* footnote format has been modified for publication of this schedule.

Age ► Vaccine ▼	Birth	1 month	2 months	4 months	6 months	12 months	15 months	18 months	19–23 months	2–3 years	4–6 years	
Hepatitis B ¹	НерВ	Не	рB	See footnote 1		Не	рВ		H	epB Seri	es	
Rotavirus ²			Rota	Rota	Rota			[
Diphtheria, Tetanus, Pertussis ³			DTaP	DTaP	DTaP		D1	aP			DTaP	Range of recommended
Haemophilus influenzae type b⁴			Hib	Hib	Hib⁴	Н	ib I		H	ib		ages
Pneumococcal⁵			PCV	PCV	PCV	P	CV			PCV PI	PV	
Inactivated Poliovirus			IPV	IPV		IF	N N				IPV	Catch-up immunization
Influenza ⁶							Influe	nza (Year	ly)			mmumzation
Measles, Mumps, Rubella ⁷						MI	MR				MMR	_
Varicella ⁸						Vari	cella				<mark>Varicella</mark>	Certain
Hepatitis A ⁹			[HepA ((2 doses)		НерА	Series	high-risk
Meningococcal ¹⁰										MP	SV4	groups

FIGURE 1. Recommended immunization schedule for persons aged 0–6 years — United States, 2007

This schedule indicates the recommended ages for routine administration of currently licensed childhood vaccines, as of December 1, 2006, for children aged 0–6 years. Additional information is available at http://www.cdc.gov/nip/recs/child-schedule.htm. Any dose not administered at the recommended age should be administered at any subsequent visit, when indicated and feasible. Additional vaccines may be licensed and recommended during the year. Licensed combination vaccines may be used whenever any components of the combination are indicated and other components

1. Hepatitis B vaccine (HepB). (Minimum age: birth) At birth:

- Administer monovalent HepB to all newborns before hospital discharge.
- If mother is hepatitis surface antigen (HBsAg)-positive, administer HepB and 0.5 mL of hepatitis B immune globulin (HBIG) within 12 hours of birth.
- If mother's HBsAg status is unknown, administer HepB within 12 hours of birth. Determine the HBsAg status as soon as possible and if HBsAg-positive, administer HBIG (no later than age 1 week).
- If mother is HBsAg-negative, the birth dose can only be delayed with physician's order and mothers' negative HBsAg laboratory report documented in the infant's medical record.

After the birth dose:

• The HepB series should be completed with either monovalent HepB or a combination vaccine containing HepB. The second dose should be administered at age 1–2 months. The final dose should be administered at age \geq 24 weeks. Infants born to HBsAg-positive mothers should be tested for HBsAg and antibody to HBsAg after completion of \geq 3 doses of a licensed HepB series, at age 9–18 months (generally at the next well-child visit).

4-month dose:

- It is permissible to administer 4 doses of HepB when combination vaccines are administered after the birth dose. If monovalent HepB is used for doses after the birth dose, a dose at age 4 months is not needed.
- 2. Rotavirus vaccine (Rota). (Minimum age: 6 weeks)
 - Administer the first dose at age 6–12 weeks. Do not start the series later than age 12 weeks.
 - Administer the final dose in the series by age 32 weeks. Do not administer a dose later than age 32 weeks.
 - Data on safety and efficacy outside of these age ranges are insufficient.
- 3. Diphtheria and tetanus toxoids and acellular pertussis vaccine (DTaP). (*Minimum age: 6 weeks*)
 - The fourth dose of DTaP may be administered as early as age 12 months, provided 6 months have elapsed since the third dose.
 - Administer the final dose in the series at age 4-6 years.
- 4. Haemophilus influenzae type b conjugate vaccine (Hib). (Minimum age: 6 weeks)
 If PRP-OMP (PedvaxHIB[®] or ComVax[®] [Merck]) is administered at ages 2 and 4 months, a dose at age 6 months is not required.
 - TriHiBit[®] (DTaP/Hib) combination products should not be used for primary immunization but can be used as boosters following any Hib vaccine in children aged ≥12 months.

of the vaccine are not contraindicated and if approved by the Food and Drug Administration for that dose of the series. Providers should consult the respective Advisory Committee on Immunization Practices statement for detailed recommendations. Clinically significant adverse events that follow immunization should be reported to the Vaccine Adverse Event Reporting System (VAERS). Guidance about how to obtain and complete a VAERS form is available at http://www.vaers. hhs.gov or by telephone, 800-822-7967.

- 5. Pneumococcal vaccine. (Minimum age: 6 weeks for pneumococcal conjugate vaccine [PCV]; 2 years for pneumococcal polysaccharide vaccine [PPV])
 - Administer PCV at ages 24–59 months in certain high-risk groups. Administer PPV to children aged ≥2 years in certain high-risk groups. See MMWR 2000;49(No. RR-9):1–35.
- 6. Influenza vaccine. (Minimum age: 6 months for trivalent inactivated influenza vaccine [TIV]; 5 years for live, attenuated influenza vaccine [LAIV])
- All children aged 6–59 months and close contacts of all children aged 0–59 months are recommended to receive influenza vaccine.
- Influenza vaccine is recommended annually for children aged ≥59 months with certain risk factors, health-care workers, and other persons (including household members) in close contact with persons in groups at high risk. See MMWR 2006;55(No. RR-10):1–41.
- For healthy persons aged 5–49 years, LAIV may be used as an alternative to TIV.
 Children receiving TIV should receive 0.25 mL if aged 6–35 months or 0.5 mL if aged ≥3 years.
- Children aged <9 years who are receiving influenza vaccine for the first time should receive 2 doses (separated by ≥4 weeks for TIV and ≥6 weeks for LAIV).
- 7. Measles, mumps, and rubella vaccine (MMR). (Minimum age: 12 months)
 Administer the second dose of MMR at age 4–6 years. MMR may be administered before age 4–6 years, provided ≥4 weeks have elapsed since the first dose and both doses are administered at age >12 months.
- 8. Varicella vaccine. (Minimum age: 12 months)
- Administer the second dose of varicella vaccine at age 4–6 years. Varicella vaccine may be administered before age 4–6 years, provided that ≥3 months have elapsed since the first dose and both doses are administered at age ≥12 months. If second dose was administered ≥28 days following the first dose, the second dose does not need to be repeated.
- 9. Hepatitis A vaccine (HepA). (Minimum age: 12 months)
 - HepA is recommended for all children aged 1 year (i.e., aged 12–23 months). The 2 doses in the series should be administered at least 6 months apart.
- Children not fully vaccinated by age 2 years can be vaccinated at subsequent visits.
 HepA is recommended for certain other groups of children, including in areas where vaccination programs target older children. See *MMWR* 2006;55(No. RR-7):1–23.
- Administer MPSV4 to children and 2–10 years with terminal complement
- Administer MPSV4 to children aged 2–10 years with terminal complement deficiencies or anatomic or functional asplenia and certain other high-risk groups. See MMWR 2005;54(No. RR-7):1–21.

The Recommended Immunization Schedules for Persons Aged 0–18 Years are approved by the Advisory Committee on Immunization Practices (http://www.cdc.gov/nip/acip), the American Academy of Pediatrics (http://www.aap.org), and the American Academy of Family Physicians (http://www.aafp.org).

Vaccine ▼ Age ►	7–10 years	11-12 YEARS	13–14 15 16–18 years years years	
Tetanus, Diphtheria, Pertussis ¹	See footnote 1	Tdap	Tdap	Range of
Human Papillomavirus ²	See footnote 2	HPV (3 doses)	HPV Series	recommended
Meningococcal ³	MPSV4	MCV4	MCV4 ³ MCV4	ages
Pneumococcal ⁴		PPV		
Influenza⁵		Influenza (Yearly)		Catch-up
Hepatitis A ⁶		immunization		
Hepatitis B ⁷		HepB Series		
Inactivated Poliovirus ⁸		IPV Series		Orantala
Measles, Mumps, Rubella ⁹		Certain high-risk		
Varicella ¹⁰		Varicella Series		groups

FIGURE 2. Recommended immunization schedule for persons aged 7–18 years — United States, 2007

This schedule indicates the recommended ages for routine administration of currently licensed childhood vaccines, as of December 1, 2006, for children aged 7–18 years. Additional information is available at http://www.cdc.gov/nip/recs/child-schedule.htm. Any dose not administered at the recommended age should be administered at any subsequent visit, when indicated and feasible. Additional vaccines may be licensed and recommended during the year. Licensed combination vaccines may be used whenever any components of the combination are indicated and other components

- 1. Tetanus and diphtheria toxoids and acellular pertussis vaccine (Tdap). (Minimum age: 10 years for BOOSTRIX[®] and 11 years for ADACEL[™])
 - Administer at age 11–12 years for those who have completed the recommended childhood DTP/DTaP vaccination series and have not received a tetanus and diphtheria toxoids vaccine (Td) booster dose.
 - Adolescents aged 13–18 years who missed the 11–12 year Td/Tdap booster dose should also receive a single dose of Tdap if they have completed the recommended childhood DTP/DTaP vaccination series.
- 2. Human papillomavirus vaccine (HPV). (Minimum age: 9 years)
 - Administer the first dose of the HPV vaccine series to females at age 11–12 years.
 Administer the second dose 2 months after the first dose and the third dose 6 months after the first dose.
 - Administer the HPV vaccine series to females at age 13–18 years if not previously vaccinated.
- 3. Meningococcal vaccine. (Minimum age: 11 years for meningococcal conjugate
 - vaccine [MCV4]; 2 years for meningococcal polysaccharide vaccine [MPSV4])
 Administer MCV4 at age 11–12 years and to previously unvaccinated adolescents at high school entry (at approximately age 15 years).
 - Administer MCV4 to previously unvaccinated college freshmen living in dormitories; MPSV4 is an acceptable alternative.
- Vaccination against invasive meningococcal disease is recommended for children and adolescents aged ≥2 years with terminal complement deficiencies or anatomic or functional asplenia and certain other high-risk groups. See MMWR 2005;54(No. RR-7):1–21. Use MPSV4 for children aged 2–10 years and MCV4 or MPSV4 for older children.
- 4. Pneumococcal polysaccharide vaccine (PPV). (Minimum age: 2 years)
 Administer for certain high-risk groups. See MMWR 1997;46(No. RR-8):1–24, and MMWR 2000;49(No. RR-9):1–35.
- 5. Influenza vaccine. (Minimum age: 6 months for trivalent inactivated influenza vaccine [TIV]; 5 years for live, attenuated influenza vaccine [LAIV])
 - Influenza vaccine is recommended annually for persons with certain risk factors, health-care workers, and other persons (including household members) in close contact with persons in groups at high risk. See MMWR 2006;55 (No. RR-10):1–41.
 - For healthy persons aged 5–49 years, LAIV may be used as an alternative to TIV.
 - Children aged <9 years who are receiving influenza vaccine for the first time should receive 2 doses (separated by ≥4 weeks for TIV and ≥6 weeks for LAIV).

of the vaccine are not contraindicated and if approved by the Food and Drug Administration for that dose of the series. Providers should consult the respective Advisory Committee on Immunization Practices statement for detailed recommendations. Clinically significant adverse events that follow immunization should be reported to the Vaccine Adverse Event Reporting System (VAERS). Guidance about how to obtain and complete a VAERS form is available at http://www.vaers. hhs.gov or by telephone, 800-822-7967.

- 6. Hepatitis A vaccine (HepA). (Minimum age: 12 months)
 - The 2 doses in the series should be administered at least 6 months apart.
 HepA is recommended for certain other groups of children, including in areas
 - where vaccination programs target older children. See *MMWR* 2006;55 (No. RR-7):1–23.
- 7. Hepatitis B vaccine (HepB). (Minimum age: birth)
- Administer the 3-dose series to those who were not previously vaccinated.
 A 2-dose series of Recombivax HB[®] is licensed for children aged 11–15 years.
- 8. Inactivated poliovirus vaccine (IPV). (Minimum age: 6 weeks)
 For children who received an all-IPV or all-oral poliovirus (OPV) series, a fourth dose is not necessary if the third dose was administered at age ≥4 years.
 - If both OPV and IPV were administered as part of a series, a total of 4 doses should be administered, regardless of the child's current age.
- 9. Measles, mumps, and rubella vaccine (MMR). (Minimum age: 12 months)
- If not previously vaccinated, administer 2 doses of MMR during any visit, with ≥4 weeks between the doses.
- 10. Varicella vaccine. (Minimum age: 12 months)
 - Administer 2 doses of varicella vaccine to persons without evidence of immunity.
 Administer 2 doses of varicella vaccine to persons aged ≤13 years at least 3 months apart. Do not repeat the second dose, if administered ≥28 days after the first dose.
 - Administer 2 doses of varicella vaccine to persons aged $\geq\!\!13$ years at least 4 weeks apart.

TABLE. Catch-up immunization schedule for persons aged 4 months–18 years who start late or who are ≥1 month behind — United States, 2007

The table below provides catch-up schedules and minimum intervals between doses for children whose vaccinations have been delayed. A vaccine series does not need to be restarted, regardless of the time that has elapsed between doses. Use the section appropriate for the child's age.

	CAIC	H-OF SCHEDULE FOR PERSU	NS AGED 4 MONTHS-6 YEARS							
Vaccine	Minimum age									
vaccille	for Dose 1	Dose 1 to Dose 2	Dose 2 to Dose 3	Dose 3 to Dose 4	Dose 4 to Dose 5					
Hepatitis B ¹	Birth	4 weeks	8 weeks (and 16 weeks after first dose)							
Rotavirus ²	6 weeks	4 weeks	4 weeks							
Diphtheria, Tetanus, Pertussis ³	6 weeks	4 weeks	4 weeks	6 months	6 months ³					
Haemophilus influenzae type b ⁴	6 weeks	4 weeks if first dose administered at age <12 months 8 weeks (as final dose) if first dose administered at age 12–14 months No further doses needed if first dose administered at age ≥15 months	4 weeks ⁴ if current age <12 months 8 weeks (as final dose) ⁴ if current age ≥12 months and second dose administered at age <15 months No further doses needed if previous dose administered at age ≥15 months	8 weeks (as final dose) This dose only necessary for children aged 12 months-5 years who received 3 doses before age 12 months						
Pneumococcal ⁵	6 weeks	4 weeks if first dose administered at age <12 months and current age <24 months 8 weeks (as final dose) if first dose administered at age ≥12 months or current age 24–59 months No further doses needed for healthy children if first dose administered at age ≥24 months	4 weeks if current age <12 months 8 weeks (as final dose) if current age ≥12 months No further doses needed for healthy children if previous dose administered at age ≥24 months	8 weeks (as final dose) This dose only necessary for children aged 12 months–5 years who received 3 doses before age 12 months						
Inactivated Poliovirus ⁶	6 weeks	4 weeks	4 weeks	4 weeks ⁶						
Measles, Mumps, Rubella ⁷	12 months	4 weeks								
Varicella ⁸	12 months	3 months								
Hepatitis A ⁹	12 months	6 months								
	CAT	CH-UP SCHEDULE FOR PE	RSONS AGED 7-18 YEARS							
Tetanus, Diphtheria/ Tetanus, Diphtheria, Pertussis ¹⁰	7 years ¹⁰	4 weeks	8 weeks if first dose administered at age <12 months 6 months if first dose administered at age ≥12 months	6 months if first dose administered at age <12 months						
Human Papillomavirus ¹¹	9 years	4 weeks	12 weeks							
Hepatitis A ⁹	12 months	6 months								
Hepatitis B ¹	Birth	4 weeks	8 weeks (and 16 weeks after first dose)							
Inactivated Poliovirus ⁶	6 weeks	4 weeks	4 weeks	4 weeks ⁶						
Measles, Mumps, Rubella ⁷	12 months	4 weeks								
Varicella ⁸	12 months	4 weeks if first dose administered at age ≥13 years 3 months if first dose administered at age <13 years								

1. Hepatitis B vaccine (HepB). (Minimum age: birth)

 Administer the 3-dose series to those who were not previously vaccinated. A 2-dose series of Recombivax HB[®] is licensed for children aged 11–15 years.

2. Rotavirus vaccine (Rota). (Minimum age: 6 weeks)

• Do not start the series later than age 12 weeks.

- Administer the final dose in the series by age 32 weeks. Do not administer a dose later than age 32 weeks.
- Data on safety and efficacy outside of these age ranges are insufficient.
- 3. Diphtheria and tetanus toxoids and acellular pertussis vaccine (DTaP). (Minimum age: 6 weeks)
- The fifth dose is not necessary if the fourth dose was administered at age ≥4 years. DTaP is not indicated for persons aged ≥7 years.
- 4. Haemophilus influenzae type b conjugate vaccine (Hib). (Minimum age: 6 weeks) Vaccine is not generally recommended for children aged ≥5 years.
- If current age <12 months and the first 2 doses were PRP-OMP (PedvaxHIB® or ComVax® [Merck]), the third (and final) dose should be administered at age 12-15 months and at least 8 weeks after the second dose.
- If first dose was administered at age 7-11 months, administer 2 doses separated by 4 weeks plus a booster at age 12-15 months.
- 5. Pneumococcal conjugate vaccine (PCV). (Minimum age: 6 weeks)
- Vaccine is not generally recommended for children aged ≥5 years. 6. Inactivated poliovirus vaccine (IPV). (Minimum age: 6 weeks)
- For children who received an all-IPV or all-oral poliovirus (OPV) series, a fourth dose is not necessary if third dose was administered at age ≥ 4 years.
- . If both OPV and IPV were administered as part of a series, a total of 4 doses should be administered, regardless of the child's current age.

- 7. Measles, mumps, and rubella vaccine (MMR). (Minimum age: 12 months)
 - The second dose of MMR is recommended routinely at age 4–6 years but may be administered earlier if desired.
 - . If not previously vaccinated, administer 2 doses of MMR during any visit with ≥4 weeks between the doses.
- 8. Varicella vaccine. (Minimum age: 12 months)
 - The second dose of varicella vaccine is recommended routinely at age 4-6 years but may be administered earlier if desired.
 - Do not repeat the second dose in persons aged <13 years if administered ≥28 days after the first dose.
- 9. Hepatitis A vaccine (HepA). (Minimum age: 12 months)
- HepA is recommended for certain groups of children, including in areas where vaccination programs target older children. See MMWR 2006;55(No. RR-7):1-23.
- 10. Tetanus and diphtheria toxoids vaccine (Td) and tetanus and diphtheria toxoids and acellular pertussis vaccine (Tdap). (Minimum ages: 7 years for • Tdap should be substituted for a single dose of Td in the primary catch-up series
 - or as a booster if age appropriate; use Td for other doses.
 - A 5-year interval from the last Td dose is encouraged when Tdap is used as a booster dose. A booster (fourth) dose is needed if any of the previous doses were administered at age <12 months. Refer to ACIP recommendations for further information. See MMWR 2006;55(No. RR-3).
- 11. Human papillomavirus vaccine (HPV). (Minimum age: 9 years)
 - Administer the HPV vaccine series to females at age 13–18 years if not previously vaccinated

Information about reporting reactions after immunization is available online at http://www.vaers.hhs.gov or by telephone via the 24-hour national toll-free information line 800-822-7967. Suspected cases of vaccine-preventable diseases should be reported to the state or local health department. Additional information, including precautions and contraindications for immunization, is available from the National Center for Immunization and Respiratory Diseases at http://www.cdc.gov/nip/default.htm or telephone, 800-CDC-INFO (800-232-4636). The Morbidity and Mortality Weekly Report (MMWR) Series is prepared by the Centers for Disease Control and Prevention (CDC) and is available free of charge in electronic format. To receive an electronic copy each week, send an e-mail message to *listserv@listserv.cdc.gov*. The body content should read SUBscribe mmwr-toc. Electronic copy also is available from CDC's Internet server at http://www.cdc.gov/mmwr or from CDC's file transfer protocol server at ftp://ftp.cdc.gov/pub/publications/mmwr. Paper copy subscriptions are available through the Superintendent of Documents, U.S. Government Printing Office, Washington, DC 20402; telephone 202-512-1800.

Data in the weekly *MMWR* are provisional, based on weekly reports to CDC by state health departments. The reporting week concludes at close of business on Friday; compiled data on a national basis are officially released to the public on the following Friday. Data are compiled in the National Center for Public Health Informatics, Division of Integrated Surveillance Systems and Services. Address all inquiries about the *MMWR* Series, including material to be considered for publication, to Editor, *MMWR* Series, Mailstop E-90, CDC, 1600 Clifton Rd., N.E., Atlanta, GA 30333 or to *www.mmwrq@cdc.gov*.

All material in the MMWR Series is in the public domain and may be used and reprinted without permission; citation as to source, however, is appreciated.

Use of trade names and commercial sources is for identification only and does not imply endorsement by the U.S. Department of Health and Human Services.

References to non-CDC sites on the Internet are provided as a service to *MMWR* readers and do not constitute or imply endorsement of these organizations or their programs by CDC or the U.S. Department of Health and Human Services. CDC is not responsible for the content of these sites. URL addresses listed in *MMWR* were current as of the date of publication.

☆U.S. Government Printing Office: 2007-623-038/40097 Region IV ISSN: 0149-2195